WO1997007668A1 - Unactivated oocytes as cytoplast recipients for nuclear transfer - Google Patents
Unactivated oocytes as cytoplast recipients for nuclear transfer Download PDFInfo
- Publication number
- WO1997007668A1 WO1997007668A1 PCT/GB1996/002098 GB9602098W WO9707668A1 WO 1997007668 A1 WO1997007668 A1 WO 1997007668A1 GB 9602098 W GB9602098 W GB 9602098W WO 9707668 A1 WO9707668 A1 WO 9707668A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- embryo
- animal
- nucleus
- oocyte
- activation
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; CARE OF BIRDS, FISHES, INSECTS; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K67/00—Rearing or breeding animals, not otherwise provided for; New breeds of animals
- A01K67/027—New breeds of vertebrates
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
- C12N15/873—Techniques for producing new embryos, e.g. nuclear transfer, manipulation of totipotent cells or production of chimeric embryos
- C12N15/877—Techniques for producing new mammalian cloned embryos
- C12N15/8773—Ovine embryos
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/48—Reproductive organs
- A61K35/54—Ovaries; Ova; Ovules; Embryos; Foetal cells; Germ cells
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
- C12N15/873—Techniques for producing new embryos, e.g. nuclear transfer, manipulation of totipotent cells or production of chimeric embryos
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
- C12N15/873—Techniques for producing new embryos, e.g. nuclear transfer, manipulation of totipotent cells or production of chimeric embryos
- C12N15/877—Techniques for producing new mammalian cloned embryos
- C12N15/8771—Bovine embryos
Definitions
- This invention relates to the generation of animals including but not being limited to genetically selected and/or modified animals, and to cells useful in their generation.
- Transfer of the donor nucleus into the oocyte cytoplasm is generally achieved by inducing cell fusion.
- In ungulates fusion is induced by application of a DC electrical pulse across the contact/fusion plane of the couplet.
- the same pulse which induces cell fusion also activates the recipient oocyte.
- embryo reconstruction further development is dependent on a large number of factors including the ability of the nucleus to direct development i.e. totipotency, developmental competence of the recipient cytoplast (i.e. oocyte maturation) , oocyte activation, embryo culture
- the morphological events which occur in the donor nucleus after transfer into an enucleated metaphase II oocyte have been studied in a number of species including mouse (Czolowiska et al . , J. Cell Sci . 69 19-34 (1984)), rabbit (Collas and Robl, Biol . Reprod. 45 455-465 (1991)), pig (Prather et al . , J. Exp. Zool . 225355-358 (1990)), cow (Kanka et al . , Mol . Reprod. Dev. 29 110-116 (1991) ) .
- NEBD donor nuclear envelope breaks down
- PCC chromosomes prematurely condense
- MPF maturation/mitosis/ meiosis promoting factor
- This activity is found in all mitotic and meiotic cells reaching a maximal activity at metaphase.
- Matured mammalian oocytes are arrested at metaphase of the 2nd meiotic division (metaphase II) and have high MPF activity.
- MPF activity declines, the second meiotic division is completed and the second polar body extruded, the chromatin then decondenses and pronuclear formation occurs.
- a method of reconstituting an animal embryo comprising transferring a diploid nucleus into an oocyte which is arrested in the metaphase of the second meiotic division without concomitantly activating the oocyte, keeping the nucleus exposed to the cytoplasm of the recipient for a period of time sufficient for the reconstituted embryo to become capable of giving rise to a live birth and subsequently activating the reconstituted embryo while maintaining correct ploidy.
- the reconstituted embryo is a single cell.
- the invention is applicable to all animals, including birds such as domestic fowl, amphibian species and fish species. In practice, however, it will be to non-human animals, especially non-human mammals, particularly placental mammals, that the greatest commercially useful applicability is presently envisaged. It is with ungulates, particularly economically important ungulates such as cattle, sheep, goats, water buffalo, camels and pigs that the invention is likely to be most useful, both as a means for cloning animals and as a means for generating transgenic animals. It should also be noted that the invention is also likely to be applicable to other economically important animal species such as, for example, horses, llamas or rodents, e.g. rats or mice, or rabbits.
- horses, llamas or rodents e.g. rats or mice, or rabbits.
- Transgenic animals may be produced from genetically altered donor cells.
- the overall procedure has a number of advantages over conventional procedures for the production of transgenic (i.e. genetically modified) animals which may be summarised as follows:
- all animals produced from embryos prepared by the invention should transmit the relevant genetic modification through the germ line as each animal is derived from a single nucleus; in contrast, production of transgenic animals by pronuclear injection or chimerism after inclusion of modified stem cell populations by blastocyst injection produces a proportion of mosaic -animals in which all cells do not contain the modification and may not transmit the modification through the germ line; and (5) cells can be selected for the site of genetic modification (e.g. integration) prior to the generation of the whole animal.
- transgenic in relation to animals, should not be taken to be limited to referring to animals containing in their germ line one or more genes from another species, although many transgenic animals will contain such a gene or genes. Rather, the term refers more broadly to any animal whose germ line has been the subject of technical intervention by recombinant DNA technology. So, for example, an animal in whose germ line an endogenous gene has been deleted, duplicated, activated or modified is a transgenic animal for the purposes of this invention as much as an animal to whose germ line an exogenous DNA sequence has been added.
- the donor nucleus is genetically modified.
- the donor nucleus may contain one or more transgenes and the genetic modification may take place prior to nuclear transfer and embryo reconstitution.
- micro ⁇ injection analogous to injection into the male or female pronucleus of a zygote, may be used as a method of genetic modification, the invention is not limited to that methodology: mass transformation or transfection techniques can also be used e.g. electroporation, viral transfection or lipofection.
- a diploid nucleus is transferred from a donor into the enucleated recipient oocyte.
- Donors which are diploid at the time of transfer are necessary in order to maintain the correct ploidy of the reconstituted embryo; therefore donors may be either in the Gl phase or preferably, as is the subject of our co-pending PCT patent application No. PCT/GB96/02099 filed today (claiming priority from GB 9517780.4) , in the GO phase of the cell cycle.
- the mitotic cell cycle has four distinct phases, G, S, G2 and M.
- the beginning event in the cell cycle, called start takes place in the Gl phase and has a unique function.
- the decision or commitment to undergo another cell cycle is made at start .
- Once a cell has passed through start it passes through the remainder of the Gl phase, which is the pre-DNA synthesis phase.
- the second stage, the S phase is when DNA synthesis takes place. This is followed by the G2 phase, which is the period between DNA synthesis and mitosis. Mitosis itself occurs at the M phase.
- Quiescent cells which include cells in which quiescence has been induced as well as those cells which are naturally quiescent, such as certain fully differentiated cells
- Quiescent cells are generally regarded as not being in any of these four phases of the cycle; they are usually described as being in a GO state, so as to indicate that they would not normally progress through the cycle.
- the nuclei of quiescent GO cells like the nuclei of Gl cells, have a diploid DNA content; both of such diploid nuclei can be used in the present invention.
- Recipient cells useful in the invention are enucleated oocytes which are arrested in the metaphase of the second meiotic division. In most vertebrates, oocyte maturation proceeds in vivo to this fairly late stage of the egg maturation process and then arrests. At ovulation, the arrested oocyte is released from the ovary (and, if fertilisation occurs, the oocyte is naturally stimulated to complete meiosis) . In the practice of the invention, oocytes can be matured either in vi tro or in vivo and are collected on appearance of the 1st polar body or as soon as possible after ovulation, respectively.
- the recipient be enucleate. While it has been generally assumed that enucleation of recipient oocytes in nuclear transfer procedures is essential, there is no published experimental confirmation of this judgement.
- the original procedure described for ungulates involved splitting the cell into two halves, one of which was likely to be enucleated (Willadsen Nature 320 (6) 63-65 (1986)). This procedure has the disadvantage that the other unknown half will still have the metaphase apparatus and that the reduction in volume of the cytoplasm is believed to accelerate the pattern of differentiation of the new embryo (Eviskov et al . , Development 109 322-328 (1990)).
- enucleation may be achieved physically, by actual removal of the nucleus, pro-nuclei or metaphase plate (depending on the recipient cell) , or functionally, such as by the application of ultraviolet radiation or another enucleating influence.
- the donor nucleus After enucleation, the donor nucleus is introduced either by fusion to donor cells under conditions which do not induce oocyte activation or by injection under non- activating conditions. In order to maintain the correct ploidy of the reconstructed embryo the donor nucleus must be diploid (i.e. in the GO or Gl phase of the cell cycle) at the time of fusion.
- nucleus of the former it is necessary for the nucleus of the former to be transferred to the latter. Most conveniently, nuclear transfer is effected by fusion. Activation should not take place at the time of fusion.
- Three established methods which have been used to induce fusion are: (1) exposure of cells to fusion-promoting chemicals, such as polyethylene glycol;
- inactivated virus such as Sendai virus
- electrical stimulation the use of electrical stimulation
- Exposure of cells to fusion-promoting chemicals such as polyethylene glycol or other glycols is a routine procedure for the fusion of somatic cells, but it has not been widely used with embryos.
- polyethylene glycol is toxic it is necessary to expose the cells for a minimum period and the need to be able to remove the chemical quickly may necessitate the removal of the zona pellucida
- inactivated Sendai virus provides an efficient means for the fusion of cells from cleavage-stage embryos (Graham Wistar Inst . Symp. Monogr. 9 19 (1969)) , with the additional experimental advantage that activation is not induced.
- fusion is commonly achieved by the same electrical stimulation that is used to induce parthogenetic activation (Willadsen Nature 320 (6) 63-65 (1986) , Prather et al . , Biol . Reprod. 37 859-866 (1987)) .
- Sendai virus induces fusion in a proportion of cases, but is not sufficiently reliable for routine application (Willadsen Nature 320 (6) 63-65 (1986)) .
- cell-cell fusion is a preferred method of effecting nuclear transfer, it is not the only method that can be used.
- Other suitable techniques include microinjection
- fusion of the oocyte karyoplast couplet is accomplished in the absence of activation by electropulsing in 0.3M mannitol solution or 0.27M sucrose solution; alternatively the nucleus may be introduced by injection in a calcium free medium.
- the age of the oocytes at the time of fusion/injection and the absence of calcium ions from the fusion/injection medium prevent_activation of the recipient oocyte.
- the fused reconstructed embryo which is generally returned to the maturation medium, is maintained without being activated so that the donor nucleus is exposed to the recipient cytoplasm for a period of time sufficient to allow the reconstructed embryo to become capable, eventually, of giving rise to a live birth (preferably of a fertile offspring) .
- the optimum period of time before activation varies from species to species and can readily be determined by experimentation. For cattle, a period of from 6 to 20 hours is appropriate. The time period should probably not be less than that which will allow chromosome formation, and it should not be so long either that the couplet activates spontaneously or, in extreme cases that it dies.
- any conventional or other suitable activation protocol can be used.
- Recent experiments have shown that the requirements for parthogenetic activation are more complicated than had been imagined. It had been assumed that activation is an all-or-none phenomenon and that the large number of treatments able to induce formation of a pronucleus were all causing "activation".
- exposure of rabbit oocytes to repeated electrical pulses revealed that only selection of an appropriate series of pulses and control of the Ca 2+ was able to promote development of diploidized oocytes to mid-gestation (Ozil Development 109 117-127 (1990) ) .
- correct ploidy must be maintained during activation. It is desirable to inhibit or stabilise microtubule polymerisation in order to prevent the production of multiple pronuclei, thereby to maintain correct ploidy.
- a microtubule inhibitor such as nocodazole at an effective concentration (such as about 5 ⁇ g/ml) .
- Colchecine and colcemid are other microtubule inhibitors.
- a microtubule stabiliser such as, for example, taxol could be used.
- microtubules The molecular component of microtubules (tubulin) is in a state of dynamic equilibrium between the polymerised and non-polymerised states.
- Microtubule inhibitors such as nocodazole prevent the addition of tubulin molecules to microtubules, thereby disturbing the equilibrium and leading to microtubule depolymerisation and destruction of the spindle. It is preferred to add the microtubule inhibitor a sufficient time before activation to ensure complete, or almost complete, depolymerisation of the microtubules. Twenty to thirty minutes is likely to be sufficient in most cases.
- a microtubule stabiliser such as taxol prevents the breakdown of the spindle and may also therefore prevent the production of multiple pronuclei.
- microtubule stabiliser is preferably under similar conditions to those used for microtubule inhibitors.
- the microtubule inhibitor or stabiliser should remain present after activation until pronuclei formation. It should be removed thereafter, and in any event before the first division takes place.
- the reconstructed oocytes are placed into medium containing nocodazole (5 ⁇ g/ml) and activated using conventional protocols. Incubation in nocodazole may be continued for 4-6 hours following the activation stimulus (dependent upon species and oocyte age) .
- a viable reconstituted animal embryo prepared by a method as described previously.
- a method of preparing an animal comprising:
- Step (a) has been described in depth above.
- step (b) in the method of this aspect of the invention is to cause an animal to develop to term from the embryo. This may be done directly or indirectly. In direct development, the reconstituted embryo from step (a) is simply allowed to develop without further intervention beyond any that may be necessary to allow the development to take place. In indirect development, however, the embryo may be further manipulated before full development takes place. For example, the embryo may be split and the cells clonally expanded, for the purpose of improving yield.
- a limitation in the presently achieved rate of blastocyst formation may be due to the fact that a majority of the embryos do not "reprogram” (although an acceptable number do) . If this is the case, then the rate may-be enhanced as follows.
- Each embryo that does develop itself can be used as a nuclear donor at the 32-64 cell stage; alternatively, inner cell mass cells can be used at the blastocyst stage. If these embryos do indeed reflect those which have reprogrammed gene expression and those nuclei are in fact reprogrammed
- each developing embryo may be multiplied in this way by the efficiency of the nuclear transfer process.
- the degree of enhancement likely to be achieved depends upon the cell type. In sheep, it is readily possible to obtain 55% blastocyst stage embryos by transfer of a single blastomere from a 16 cell embryo to a preactivated "Universal Recipient" oocyte. So it is reasonable to hypothesise that each embryo developed from a single cell could give rise to eight at the 16 cell stage. Although these figures are just a rough guide, it is clear that at later developmental stages the extent of benefit would depend on the efficiency of the process at that stage. Aside from the issue of yield-improving expediencies, the reconstituted embryo may be cultured, in vivo or in vi tro to blastocyst.
- embryos derived by nuclear transfer are different from normal embryos and sometimes benefit from or even require culture conditions in vivo other than those in which embryos are usually cultured
- the function of the protective agar or other medium is twofold: first, it acts as a structural aid for the embryo by holding the zona pellucida together; and secondly it acts as barrier to cells of the recipient animal's immune system.
- the embryo may be screened for suitability for development to term. Typically, this will be done where the embryo is transgenic and screening and selection for stable integrants has been carried out. Screening for non-transgenic genetic markers may also be carried out at this stage. However, because the method of the invention allows for screening of donors at an earlier stage, that will generally be preferred.
- blastocyst embryo After screening, if screening has taken place, the blastocyst embryo is allowed to develop to term. This will generally be in vivo. If development up to blastocyst has taken place in vi tro, then transfer into the final recipient animal takes place at this stage. If blastocyst development has taken place in vivo, although in principle the blastocyst can be allowed to develop to term in the pre-blastocyst host, in practice the blastocyst will usually be removed from the (temporary) pre-blastocyst recipient and, after dissection from the protective medium, will be " transferred to the (permanent) post-blastocyst recipient.
- animals may be bred from the animal prepared by the preceding steps. In this way, an animal may be used to establish a herd or flock of animals having the desired genetic characteristic(s) .
- transgenesis for example by transfection with suitable constructs, with or without selectable markers;
- (2a) optionally screen and select for stable integrants - skip for micro-injection
- the chromatin of the donor nucleus can be exposed to the meiotic cytoplasm of the recipient oocyte in the absence of activation for appropriate periods of time. This may increase the "reprogramming" of the donor nucleus by altering the chromatin structure.
- FIGURE 1 shows the rate of maturation of bovine oocytes in vi tro .
- Example 1 "MAGIC" Procedure using Bovine Oocytes Recipient oocytes the subject of this experimental procedure are designated MAGIC (Metaphase Arrested G1/G0 Accepting Cytoplast) Recipients.
- FIG. 1 ovaries were obtained from a local abattoir and maintained at 28-32°C during transport to the laboratory. Cumulus oocyte complexes (COC's) were aspirated from follicles 3-10mm in diameter using a hypodermic needle (1.2mm internal diameter) and placed into sterile plastic universal containers. The universal containers were placed into a warmed chamber (35°C) and the follicular material allowed to settle for 10-15 minutes before pouring off three quarters of the supernatant.
- COC's Cumulus oocyte complexes
- the remaining follicular material was diluted with an equal volume of dissection medium (TCM 199 with Earles salts (Gibco), 75.0 mg/l kanamycin, 30.OmM Hepes, pH 7.4, osmolarity 280 mOsmols/Kg H 2 0) supplemented with 10% bovine serum, transferred into an 85mm petri dish and searched for COC's under a dissecting microscope.
- TCM 199 with Earles salts (Gibco) 75.0 mg/l kanamycin, 30.OmM Hepes, pH 7.4, osmolarity 280 mOsmols/Kg H 2 0
- bovine follicular oocytes If maturation is then continued until 24 hours these oocytes activate at a very low rate (24%) in mannitol containing calcium (Table la) . However, removal of calcium and magnesium from the electropulsing medium prevents any activation.
- Table la shows activation of bovine follicular oocytes matured in vi tro for different periods. Oocytes were removed from the maturation medium, washed once in activation medium, placed into the activation chamber and given a single electrical pulse of 1.25kV/cm for 80 ⁇ s. Table la
- Table lb shows activation response of in vitro matured bovine oocytes sham enucleated at approximately 22 hours post onset of maturation (hpm) .
- Oocytes were treated exactly as for enucleation, a small volume of cytoplasm was aspirated not containing the metaphase plate.
- the oocytes were given a single DC pulse of 1.25 KV/cm and returned to the maturation medium, at 30 hpm and 42 hpm groups of oocytes were mounted, fixed and stained with aceto-orcein. The results show the number of oocytes at each time point from five individual experiments as the number of cells having pronuclei with respect to the total number of cells.
- hpm hours post onset of maturation
- Table 2 shows pronuclear formation in enucleated oocytes fused to primary bovine fibroblasts (24 hpm) and subsequently activated (42hpm) .
- the results represent five separate experiments. Oocytes were divided into two groups, group A were incubated in nocodazole for 1 hour prior to activation and for 6 hours following activation. Group B were not treated with nocodazole. Activated oocytes were fixed and stained with aceto-orcein 12 hours post activation. The number of pronuclei (PN) in each parthenote was then scored under phase contrast. The results are expressed as the percentage of activated oocytes containing 1 or more pronuclei.
- enucleated oocytes can be fused to donor blastomeres/cells in either 0.3M mannitol or 0.27M sucrose alternatively the donor the cells or nuclei can be injected in calcium free medium in the absence of any activation response;
- reconstructed embryos or enucleated pulsed oocytes can be cultured in maturation medium and do not undergo spontaneous activation;
- the transferred nucleus is seen to undergo nuclear envelope breakdown (NEBD) and chromosome condensation. No organised meiotic/mitotic spindle is observed regardless of the cell cycle stage of the transferred nucleus;
- Table 3 shows development of bovine embryos reconstructed by nuclear transfer of serum starved (GO) bovine primary fibroblasts into enucleated unactivated Mil oocytes. Embryos were reconstructed at 24 hpm and the fused couplets activated at 42 hpm. Fused couplets were incubated in nocodazole (5 ⁇ g/ml) in M2 medium for 1 hour prior to activation and 5 hours post activation. Couplets were activated with a single DC pulse of 1.25 KV/cm for 80 ⁇ sec.
- Table 4 shows development of ovine embryos reconstructed by transfer of an embryo derived established cell line to unactivated enucleated in vivo matured ovine oocytes.
- Oocytes were obtained from superstimulated Scottish blackface ewes, the cell line was established from the embryonic disc of a day 9 embryo obtained from a Welsh mountain ewe.
- Reconstructed embryos were cultured in the ligated oviduct of a temporary recipient ewe for 6 days, recovered and assessed for development.
- Table 5 shows induction of pregnancy following transfer of all morula/blastocyst stage reconstructed embryos to the uterine horn of synchronised final recipient blackface ewes.
- the table shows the total number of embryos from each group transferred the frequency of pregnancy in terms of ewes and embryos, in the majority of cases 2 embryos were transferred to each ewe.
- a single twin pregnancy was established which resulted in the birth of a single live lamb.
Abstract
Description
Claims
Priority Applications (26)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
BR9610013-3A BR9610013A (en) | 1995-08-31 | 1996-08-30 | Processes for reconstituting an animal embryo and for preparing an animal, reconstituted animal embryo, and, animal |
IL12341796A IL123417A0 (en) | 1995-08-31 | 1996-08-30 | Unactivated oocytes as cytoplast recipients for nuclear transfer |
DK96928586T DK0847237T3 (en) | 1995-08-31 | 1996-08-30 | Non-activated oocytes as cytoplast recipients for nuclear transfer |
AU68309/96A AU728809B2 (en) | 1995-08-31 | 1996-08-30 | Unactivated oocytes as cytoplast recipients for nuclear transfer |
EP96928586A EP0847237B1 (en) | 1995-08-31 | 1996-08-30 | Unactivated oocytes as cytoplast recipients for nuclear transfer |
NZ316148A NZ316148A (en) | 1995-08-31 | 1996-08-30 | Reconstituting animal embryos by transferring nuclei into unactivated oocytes |
GB9802916A GB2318792B (en) | 1995-08-31 | 1996-08-30 | Unactivated oocytes as cytoplast recipients for nuclear transfer |
JP9509995A JP2000506721A (en) | 1995-08-31 | 1996-08-30 | Inactive oocytes as recipient cytoplasm for nuclear transfer |
DE69637591T DE69637591D1 (en) | 1995-08-31 | 1996-08-30 | INACTIVATED OOCYTES AS CYTOPLASMIC RECEPTORS FOR CORE TRANSFER |
US08/803,165 US6252133B1 (en) | 1995-08-31 | 1997-02-19 | Unactivated oocytes as cytoplast recipients of quiescent and non-quiescent cell nuclei, while maintaining correct ploidy |
NO980846A NO980846L (en) | 1995-08-31 | 1998-02-27 | Unactivated oocytes as cytoplasmic receivers for nuclear transfers |
HK98104135A HK1004937A1 (en) | 1995-08-31 | 1998-05-13 | Unactiviated oocytes as cytoplast recipients for nuclear transfer |
US09/650,285 US6525243B1 (en) | 1995-08-31 | 2000-08-29 | Unactivated oocytes as cytoplast recipients of quiescent cell nuclei while maintaining correct ploidy |
US09/973,701 US20030037352A1 (en) | 1995-08-31 | 2001-10-11 | Unactivated oocytes as cytoplast recipients for nuclear transfer |
US09/989,126 US7332648B2 (en) | 1995-08-31 | 2001-11-21 | Unactivated oocytes in nuclear transfer to produce cultured inner cell mass cells and ungulates |
US09/989,128 US7307198B2 (en) | 1995-08-31 | 2001-11-21 | Ungulates produced by nuclear transfer of G1 cells |
US09/989,125 US7304204B2 (en) | 1995-08-31 | 2001-11-21 | Ungulates produced by nuclear transfer of G1 cells |
US10/190,617 US7326824B2 (en) | 1995-08-31 | 2002-07-09 | Unactivated ungulate oocytes to produce a transgenic ungulate by nuclear transfer |
US10/234,854 US7321075B2 (en) | 1995-08-31 | 2002-09-05 | Serial nuclear transfer of ungulate embryos |
US10/909,845 US7329796B2 (en) | 1995-08-31 | 2004-08-03 | Serial nuclear transfer of ungulate embryos |
US10/914,161 US7321076B2 (en) | 1995-08-31 | 2004-08-10 | Unactivated ungulate oocytes to produce a cloned ungulate by nuclear transfer |
US11/068,903 US7432415B2 (en) | 1995-08-31 | 2005-03-02 | Unactivated oocytes as cytoplast recipients for nonprimate mammalian and pig nuclear transfer |
US11/265,114 US7524677B2 (en) | 1995-08-31 | 2005-11-03 | Mammalian cultured inner cell mass cell culture using a g1 cell as nuclear donor |
US11/543,881 US7326825B2 (en) | 1995-08-31 | 2006-10-06 | Methods of ungulate nuclear transfer |
US11/544,038 US20070028312A1 (en) | 1995-08-31 | 2006-10-06 | Unactivated oocytes as cytoplast recipients for nuclear transfer |
US12/647,316 US20100146654A1 (en) | 1995-08-31 | 2009-12-24 | Unactivated oocytes as cytoplast recipients for nuclear transfer |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GB9517779.6 | 1995-08-31 | ||
GBGB9517779.6A GB9517779D0 (en) | 1995-08-31 | 1995-08-31 | Biological manipulation |
Related Child Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US08/803,165 Continuation US6252133B1 (en) | 1995-08-31 | 1997-02-19 | Unactivated oocytes as cytoplast recipients of quiescent and non-quiescent cell nuclei, while maintaining correct ploidy |
Publications (1)
Publication Number | Publication Date |
---|---|
WO1997007668A1 true WO1997007668A1 (en) | 1997-03-06 |
Family
ID=10779997
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/GB1996/002098 WO1997007668A1 (en) | 1995-08-31 | 1996-08-30 | Unactivated oocytes as cytoplast recipients for nuclear transfer |
Country Status (23)
Country | Link |
---|---|
US (12) | US6252133B1 (en) |
EP (1) | EP0847237B1 (en) |
JP (3) | JP2000506721A (en) |
KR (4) | KR100743006B1 (en) |
CN (3) | CN1772891A (en) |
AT (1) | ATE400176T1 (en) |
AU (1) | AU728809B2 (en) |
BR (1) | BR9610013A (en) |
CA (1) | CA2229657A1 (en) |
CZ (1) | CZ60498A3 (en) |
DE (1) | DE69637591D1 (en) |
DK (1) | DK0847237T3 (en) |
ES (1) | ES2309989T3 (en) |
GB (1) | GB9517779D0 (en) |
HK (1) | HK1004937A1 (en) |
HU (1) | HUP9802485A3 (en) |
IL (1) | IL123417A0 (en) |
NO (1) | NO980846L (en) |
NZ (2) | NZ335407A (en) |
PL (1) | PL325336A1 (en) |
SG (1) | SG75919A1 (en) |
WO (1) | WO1997007668A1 (en) |
ZA (1) | ZA967383B (en) |
Cited By (144)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1998030683A2 (en) * | 1997-01-10 | 1998-07-16 | University Of Massachusetts, A Public Institution Of Higher Education Of The Commonwealth Of Massachusetts | Nuclear transfer with differentiated fetal and adult donor cells |
EP0930362A2 (en) * | 1997-10-28 | 1999-07-21 | Snow Brand Milk Products Co., Ltd. | Method of synchronizing epithelial cells into Go phase |
WO1999035906A1 (en) * | 1998-01-16 | 1999-07-22 | Agrobiogen Gmbh | Efficient nuclear transfer using primordial germ cells |
WO1999037143A2 (en) * | 1998-01-21 | 1999-07-29 | University Of Hawaii | Full term development of animals from enucleated oocytes reconstituted with adult somatic cell nuclei |
WO1999046982A1 (en) * | 1998-03-16 | 1999-09-23 | Relag Pty Ltd | Porcine nuclear transfer |
WO1999053025A1 (en) * | 1998-04-15 | 1999-10-21 | Monash University | Method of nuclear transfer |
WO1999053751A1 (en) * | 1998-04-20 | 1999-10-28 | Consorzio Incremento Zootecnico S.R.L. | Source of nuclei for nuclear transfer |
WO2000001806A1 (en) * | 1998-07-07 | 2000-01-13 | University Of Hawaii | Use of the first polar body chromosomes for the production of embryos |
US6025155A (en) * | 1996-04-10 | 2000-02-15 | Chromos Molecular Systems, Inc. | Artificial chromosomes, uses thereof and methods for preparing artificial chromosomes |
WO2000018902A1 (en) * | 1998-09-25 | 2000-04-06 | Roslin Institute (Edinburgh) | Method of screening for large offspring syndrome |
WO2000022098A1 (en) * | 1998-10-12 | 2000-04-20 | Geron Bio-Med Limited | Porcine oocytes with improved developmental competence |
WO2000030436A1 (en) | 1998-11-19 | 2000-06-02 | Ppl Therapeutics (Scotland) Ltd. | Stabilisation of milk from transgenic animals |
US6077697A (en) * | 1996-04-10 | 2000-06-20 | Chromos Molecular Systems, Inc. | Artificial chromosomes, uses thereof and methods for preparing artificial chromosomes |
EP1017423A1 (en) | 1997-07-03 | 2000-07-12 | University of Massachusetts, a Public Institution of Higher Education of The Commonwealth of Massachusetts, | Cloning pigs using donor nuclei from differentiated cells |
EP1017422A1 (en) | 1997-07-03 | 2000-07-12 | University of Massachusetts, a Public Institution of Higher Education of The Commonwealth of Massachusetts, | Cloning using donor nuclei from non-serum starved, differentiated cells |
WO2000042174A1 (en) * | 1999-01-13 | 2000-07-20 | Ppl Therapeutics (Scotland) Limited | Double nuclear transfer method and results thereof |
WO2000051424A2 (en) * | 1999-03-04 | 2000-09-08 | Ppl Therapeutics (Scotland) Ltd. | Genetic modification of somatic cells and uses thereof |
WO2001000794A1 (en) * | 1999-06-30 | 2001-01-04 | Hwang, Woo-Suk | Method for producing cloned tigers by employing inter-species nuclear transplantation technique |
WO2001000795A1 (en) * | 1999-06-30 | 2001-01-04 | Hwang, Woo-Suk | A method for producing cloned cows |
WO2001000793A1 (en) * | 1999-06-30 | 2001-01-04 | Hwang, Woo-Suk | Method for producing human cloned embryos by employing inter-species nuclear transplantation technique |
WO2001035734A1 (en) * | 1999-11-19 | 2001-05-25 | Korea Research Institute Of Bioscience And Biotechnolgoy | An improved method for production of porcine clone embryos via somatic cell nuclear transfer |
WO2001036646A1 (en) * | 1999-11-19 | 2001-05-25 | Cancer Research Ventures Limited | Inhibiting gene expression with dsrna |
US6258998B1 (en) | 1998-11-24 | 2001-07-10 | Infigen, Inc. | Method of cloning porcine animals |
US6271436B1 (en) | 1996-10-11 | 2001-08-07 | The Texas A & M University System | Cells and methods for the generation of transgenic pigs |
WO2001059076A2 (en) * | 2000-02-09 | 2001-08-16 | The Government Of The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Premeiotic and postmeiotic origin of teratomas: isolated teratoma stem cells for therapeutic uses |
WO2001094636A2 (en) | 2000-06-05 | 2001-12-13 | Genetics Inst | Compositions, kits, and methods for identification and modulation of type i diabetes |
WO2002000730A2 (en) | 2000-06-28 | 2002-01-03 | Genetics Institute, Llc. | Pd-l2 molecules: novel pd-1 ligands and uses therefor |
WO2002028164A2 (en) * | 2000-10-06 | 2002-04-11 | Advanced Cell Technology, Inc. | Cloning endangered and extinct species |
US6395958B1 (en) | 1997-03-06 | 2002-05-28 | Infigen, Inc. | Method of producing a polypeptide in an ungulate |
WO2002064799A2 (en) | 1999-09-28 | 2002-08-22 | Transkaryotic Therapies, Inc. | Optimized messenger rna |
WO2002079499A1 (en) | 2001-04-02 | 2002-10-10 | Wyeth | Pd-1, a receptor for b7-4, and uses therefor |
US6489536B2 (en) * | 2001-03-07 | 2002-12-03 | Director General Of National Agricultural Research Organization | Method for producing cloned bovines from cells of a bovine intramuscular preadipocyte cell line |
WO2002102997A2 (en) * | 2000-11-30 | 2002-12-27 | Stemron Inc. | Isolated homozygous stem cells differentiated cells derived therefrom and materials and methods for making and using same |
WO2002103350A1 (en) * | 2001-06-14 | 2002-12-27 | Infigen, Inc. | Methods for cloning mammals using remodeling factors |
WO2003042362A2 (en) | 2001-11-09 | 2003-05-22 | Dana-Farber Cancer Institute, Inc. | PGC-1β, A NOVEL PGC-1 HOMOLOGUE AND USES THEREFOR |
WO2003046129A2 (en) * | 2001-11-09 | 2003-06-05 | Trustees Of The University Of Pennsylvania | Compositions for the derivation of germ cells from stem cells and methods of use thereof |
WO2003085105A1 (en) * | 2002-04-01 | 2003-10-16 | Gtc Biotherapeutics, Inc. | A method for selecting cell lines to be used for nuclear transfer in mammalian species |
US6635802B1 (en) * | 2000-01-10 | 2003-10-21 | The Texas A&M University System | Nuclear transfer using cells cultured in serum starvation media containing apoptosis inhibitors |
US6673987B1 (en) | 2000-03-24 | 2004-01-06 | Geron Corporation | Strategy for maintaining pregnancy |
US6700037B2 (en) | 1998-11-24 | 2004-03-02 | Infigen, Inc. | Method of cloning porcine animals |
US6753457B2 (en) | 1993-02-03 | 2004-06-22 | Tranxenogen | Nuclear reprogramming using cytoplasmic extract |
US6781030B1 (en) * | 1998-11-02 | 2004-08-24 | Trustee Of Tufts College, Ballou Hall | Methods for cloning mammals using telophase oocytes |
WO2005017119A2 (en) | 2003-08-14 | 2005-02-24 | Exelixis, Inc. | Ups as modifiers of the beta catenin pathway and methods of use |
WO2005046450A2 (en) | 2003-11-12 | 2005-05-26 | Children's Hospital Medical Center | Method for diagnosis and treatment of pulmonary disorders |
US6906238B2 (en) | 2000-03-15 | 2005-06-14 | University Of Georgia Research Foundation, Inc. | Effective nuclear reprogramming in mammals using CDK2 inhibitors |
WO2005111241A2 (en) | 2004-05-07 | 2005-11-24 | Applera Corporation | Genetic polymorphisms associated with liver fibrosis methods of detection and uses thereof |
US7045677B2 (en) | 1999-06-23 | 2006-05-16 | Pharming Intellectual Property Bv | Fusion proteins incorporating lysozyme |
US7071372B2 (en) | 2000-01-04 | 2006-07-04 | University Of Connecticut | Method for cloning animals with targetted genetic alterations by transfer of long-term cultured male or female somatic cell nuclei, comprising artificially-induced genetic alterations, to enucleated recipient cells |
EP1676920A2 (en) | 1997-03-26 | 2006-07-05 | Imperial College Innovations Limited | Anticoagulant fusion protein anchored to cell membrane |
EP1692936A1 (en) | 2000-10-03 | 2006-08-23 | GIE-CERBM, Centre Europeen de Recherche en Biologie et en Médecine | Method for targeted conditional DNA recombination in mice using the cre-ert2 fusion protein |
US7122177B2 (en) | 2000-01-20 | 2006-10-17 | Diabcell Pty Ltd. | Preparation and xenotransplantation of porcine islets |
US7122361B2 (en) | 2002-10-10 | 2006-10-17 | Wyeth | Compositions employing a novel human kinase |
US7129084B2 (en) | 2000-08-03 | 2006-10-31 | Therapeutic Human Polyclonals, Inc. | Production of humanized antibodies in transgenic animals |
US7169963B2 (en) | 2000-08-15 | 2007-01-30 | Board Of Trustees Of The University Of Illinois | Mammals expressing IGF-1 and alpha-lactalbumin in their milk |
WO2007035953A2 (en) | 2005-09-23 | 2007-03-29 | Celera Diagnostics, Llc. | Genetic polymorphisms associated with cardiovascular disorders and drug response, methods of detection and uses thereof |
US7208306B2 (en) | 2002-10-24 | 2007-04-24 | Wyeth | Compositions employing a novel human protein phosphatase |
WO2007050705A2 (en) | 2005-10-26 | 2007-05-03 | Celera Diagnostics, Llc. | Genetic polymorphisms associated with alzheimer's disease, methods of detection and uses thereof |
US7297525B2 (en) | 2002-11-27 | 2007-11-20 | Wyeth | Composition employing a novel human kinase |
EP1860199A2 (en) | 2001-01-12 | 2007-11-28 | Exelixis, Inc. | Modulating insulin receptor signaling |
EP1900815A2 (en) | 2001-07-12 | 2008-03-19 | University of Massachusetts | In vivo production of small interfering RNAs that mediate gene silencing |
WO2008033239A2 (en) | 2006-09-11 | 2008-03-20 | Applera | Genetic polymorphisms associated with psoriasis, methods of detection and uses thereof |
US7351876B2 (en) | 1998-01-16 | 2008-04-01 | Agrobiogen Gmbh Biotechnologie | Efficient nuclear transfer with primordial gametes |
WO2008051511A2 (en) | 2006-10-20 | 2008-05-02 | Applera Corporation | Genetic polymorphisms associated with venous thrombosis, methods of detection and uses thereof |
EP1998177A2 (en) | 2003-01-06 | 2008-12-03 | Wyeth | Compositions and methods for diagnosing and treating colon cancers |
EP2051077A2 (en) | 2003-10-07 | 2009-04-22 | Millennium Pharmaceuticals, Inc. | Nucleic acid molecules and proteins for the identification, assessment, prevention, and therapy of ovarian cancer |
WO2009061799A2 (en) | 2007-11-05 | 2009-05-14 | Celera Corporation | Genetic polymorphisms associated with liver fibrosis, methods of detection and uses thereof |
WO2009114185A2 (en) | 2008-03-12 | 2009-09-17 | The Rockefeller University | Methods and compositions for translational profiling and molecular phenotyping |
US7612250B2 (en) | 2002-07-29 | 2009-11-03 | Trustees Of Tufts College | Nuclear transfer embryo formation method |
US7611839B2 (en) | 2002-11-21 | 2009-11-03 | Wyeth | Methods for diagnosing RCC and other solid tumors |
EP2113572A1 (en) | 2005-03-11 | 2009-11-04 | Celera Corporation | Genetic polymorphisms associated with coronary heart disease, methods of detection and uses thereof |
EP2138583A1 (en) | 2000-12-22 | 2009-12-30 | Institut National De La Recherche Agronomique | Position-independent and tissue specific expression of a transgene in milk of transgenic animals |
EP2151507A1 (en) | 2002-12-20 | 2010-02-10 | Celera Corporation | Genetic polymorphisms associated with myocardial infarction, methods of detection and uses thereof |
EP2186913A2 (en) | 2003-11-26 | 2010-05-19 | Celera Corporation | Genetic polymorphisms associated with cardiovascular disorders and drug response, methods of detection and uses thereof |
WO2010080985A1 (en) | 2009-01-08 | 2010-07-15 | Dana-Farber Cancer Institute, Inc. | Compositions and methods for induced brown fat differentiation |
US7807863B2 (en) | 2002-11-08 | 2010-10-05 | Kyowa Hakko Kirin Co., Ltd. | Transgenic bovine having reduced prion protein activity and uses thereof |
EP2258718A1 (en) | 2001-04-16 | 2010-12-08 | Wyeth Holdings Corporation | Streptococcus pneumoniae open reading frames encoding polypeptide antigens and uses thereof |
EP2267153A1 (en) | 2009-05-26 | 2010-12-29 | Université Claude Bernard Lyon 1 | Identification of netrin-1 receptor unc5c gene mutation in solid cancers |
WO2011002988A1 (en) | 2009-07-01 | 2011-01-06 | Transposagen Biopharmaceuticals, Inc. | Genetically modified rat models for severe combined immunodeficiency (scid) |
EP2275559A2 (en) | 1999-09-28 | 2011-01-19 | Shire Human Genetic Therapies, Inc. | Optimized messenger RNA |
WO2011011678A2 (en) | 2009-07-24 | 2011-01-27 | Transposagen Biopharmaceuticals, Inc. | Genetically modified rat models for cytokine-cytokine signaling pathways |
WO2011014721A2 (en) | 2009-07-30 | 2011-02-03 | Transposagen Biopharmaceuticals, Inc. | Genetically modified rat models for pharmacokinetics |
WO2011017518A2 (en) | 2009-08-05 | 2011-02-10 | Transposagen Biopharmaceuticals, Inc. | Genetically modified rat models for drug metabolism |
US7888325B2 (en) | 1999-01-28 | 2011-02-15 | Medical College Of Georgia Research Institute, Inc. | Composition and method for in vivo and in vitro attenuation of gene expression using double stranded RNA |
WO2011022634A2 (en) | 2009-08-20 | 2011-02-24 | Transposagen Biopharmaceuticals, Inc. | Genetically modified rat models for pain |
EP2295606A1 (en) | 2000-11-28 | 2011-03-16 | Wyeth LLC | Expression analysis of KIAA nucleic acids and polypeptides useful in the diagnosis and treatment of prostate cancer |
EP2301947A2 (en) | 1999-02-26 | 2011-03-30 | Millennium Pharmaceuticals, Inc. | Secreted proteins and uses thereof |
EP2305836A1 (en) | 2002-08-20 | 2011-04-06 | Millennium Pharmaceuticals, Inc. | Compositions, kits and methods for identification, assessment, prevention and therapy of cervical cancer |
US7923216B2 (en) | 1997-08-14 | 2011-04-12 | Institut Pasteur | In vivo modulation of neuronal transport |
US7923015B2 (en) | 1997-08-14 | 2011-04-12 | Institut Pasteur | Methods for direct visualization of active synapses |
US7928285B2 (en) | 2004-04-22 | 2011-04-19 | Kyowa Hakko Kirin Co., Ltd. | Method of producing xenogenous antibodies using a bovine |
EP2314692A2 (en) | 2003-06-02 | 2011-04-27 | University of Massachusetts | Methods and compositions for enhancing the efficacy and specificity of RNAi |
EP2316976A1 (en) | 2000-11-28 | 2011-05-04 | Wyeth LLC | Expression analysis of FKBP nucleic acids and polypeptides useful in the diagnosis and treatment of prostate cancer |
EP2322558A1 (en) | 1999-06-30 | 2011-05-18 | Millennium Pharmaceuticals, Inc. | Antibodies directed against glycoprotein VI and uses thereof |
EP2345720A2 (en) | 2001-07-12 | 2011-07-20 | University of Massachusetts | In vivo production of small interfering RNAs that mediate gene silencing |
WO2011091134A2 (en) | 2010-01-22 | 2011-07-28 | Dana-Farber Cancer Institute, Inc. | Compositions,kits, and methods for identification, assessment, prevention, and therapy of metabolic disorders |
WO2011095894A2 (en) | 2010-02-04 | 2011-08-11 | Jichi Medical University | Identification, assessment, and therapy of cancers with innate or acquired resistance to alk inhibitors |
EP2360254A1 (en) | 1999-08-23 | 2011-08-24 | Dana-Farber Cancer Institute, Inc. | Assays for screening anti-pd-1 antibodies and uses thereof |
WO2011130340A1 (en) | 2010-04-15 | 2011-10-20 | St. Jude Children's Research Hospital | Methods and compositions for the diagnosis and treatment of cancer resistant to anaplastic lymphoma kinase (alk) kinase inhibitors |
WO2011133418A1 (en) | 2010-04-19 | 2011-10-27 | Celera Corporation | Genetic polymorphisms associated with statin response and cardiovascular diseases, methods of detection and uses thereof |
WO2012061502A2 (en) | 2010-11-02 | 2012-05-10 | Celera Corporation | Genetic polymorphisms associated with venous thrombosis and statin response, methods of detection and uses thereof |
WO2012112586A1 (en) | 2011-02-14 | 2012-08-23 | Revivicor, Inc. | Genetically modified pigs for xenotransplantation of vascularized xenografts and derivatives thereof |
WO2012129198A1 (en) | 2011-03-23 | 2012-09-27 | Transposagen Biopharmaceuticals, Inc. | Genetically modified rat models for obesity and diabetes |
US8288094B2 (en) | 2008-04-09 | 2012-10-16 | Institut Pasteur | APOBEC3 mediated DNA editing |
US8367066B2 (en) | 2004-12-10 | 2013-02-05 | Pheromonicin Biotech, Ltd | Antiviral bifunctional molecules, methods of construction and methods of treating virus-induced cancer therewith |
WO2013039996A1 (en) | 2011-09-13 | 2013-03-21 | Dana-Farber Cancer Institute, Inc. | Compositions and methods for brown fat induction and activity using fndc5 |
US8663980B2 (en) | 2007-10-26 | 2014-03-04 | Janssen Biotech, Inc. | Vectors, host cells, and methods of production and uses |
WO2014039983A1 (en) | 2012-09-07 | 2014-03-13 | The Trustees Of Dartmouth College | Vista modulators for diagnosis and treatment of cancer |
US8722964B2 (en) | 2009-04-23 | 2014-05-13 | Transposagen Biopharmaceuticals, Inc. | Genetically engineered or transgenic rats exhibiting a cancer phenotype due to a disruption of germline tumor suppressor genes |
EP2733222A1 (en) | 2008-07-09 | 2014-05-21 | Celera Corporation | Genetic polymorphisms associated with cardiovascular diseases, methods of detection and uses thereof |
US8889639B2 (en) | 2004-10-22 | 2014-11-18 | Dana-Farber Cancer Institute, Inc. | Compositions and methods for modulating PGC-1β to treat lipid-related diseases and disorders |
US8981061B2 (en) | 2001-03-20 | 2015-03-17 | Novo Nordisk A/S | Receptor TREM (triggering receptor expressed on myeloid cells) and uses thereof |
US9000127B2 (en) | 2012-02-15 | 2015-04-07 | Novo Nordisk A/S | Antibodies that bind and block triggering receptor expressed on myeloid cells-1 (TREM-1) |
US9051566B2 (en) | 2001-01-31 | 2015-06-09 | Alnylam Pharmaceuticals, Inc. | Post-transcriptional gene silencing using expressed double stranded RNA |
US9273111B2 (en) | 2004-11-29 | 2016-03-01 | Universite De Lorraine | Therapeutic TREM-1 peptides |
EP3031470A2 (en) | 2005-09-09 | 2016-06-15 | The Johns Hopkins University | Manipulation of regulatory t cell and dc function by targeting neuritin gene using antibodies, agonists and antagonists |
WO2016094481A1 (en) | 2014-12-09 | 2016-06-16 | Regeneron Pharmaceuticals, Inc. | Non-human animals having a humanized cluster of differentiation 274 gene |
EP3048175A1 (en) | 2008-02-20 | 2016-07-27 | Celera Corporation | Genetic polymorphism associated with stroke, therapy based on the detection of the polymorphism and use of kits containing reagents for detecting the polymorphism |
US9550830B2 (en) | 2012-02-15 | 2017-01-24 | Novo Nordisk A/S | Antibodies that bind and block triggering receptor expressed on myeloid cells-1 (TREM-1) |
EP3138403A1 (en) | 2005-08-09 | 2017-03-08 | Revivicor, Inc. | Transgenic ungulates expressing ctla4-ig and uses thereof |
EP3153521A1 (en) | 2010-03-26 | 2017-04-12 | Trustees of Dartmouth College | Vista regulatory t cell mediator protein, vista binding agents and use thereof |
WO2017075329A2 (en) | 2015-10-29 | 2017-05-04 | Dana-Farber Cancer Institute, Inc. | Methods for identification, assessment, prevention, and treatment of metabolic disorders using pm20d1 and n-lipidated amino acids |
US9663568B2 (en) | 2012-02-15 | 2017-05-30 | Novo Nordisk A/S | Antibodies that bind peptidoglycan recognition protein 1 |
US9701940B2 (en) | 2005-09-19 | 2017-07-11 | Histogenics Corporation | Cell-support matrix having narrowly defined uniformly vertically and non-randomly organized porosity and pore density and a method for preparation thereof |
US9820475B2 (en) | 2011-05-16 | 2017-11-21 | The Curators Of The University Of Missouri | Porcine reproductive and respiratory syndrome virus resistant animals |
US10077420B2 (en) | 2014-12-02 | 2018-09-18 | Histogenics Corporation | Cell and tissue culture container |
US10091975B2 (en) | 2015-08-06 | 2018-10-09 | The Curators Of The University Of Missouri | Pathogen-resistant animals having modified CD163 genes |
EP3421486A1 (en) | 2012-06-22 | 2019-01-02 | The Trustees Of Dartmouth College | Novel vista-ig constructs and the use of vista-ig for treatment of autoimmune, allergic and inflammatory disorders |
US10179814B2 (en) | 2014-07-17 | 2019-01-15 | Novo Nordisk A/S | Site directed mutagenesis of TREM-1 antibodies for decreasing viscosity |
EP3502252A1 (en) | 2003-06-02 | 2019-06-26 | University of Massachusetts | Methods and compositions for controlling efficacy of rna silencing |
US10370455B2 (en) | 2014-12-05 | 2019-08-06 | Immunext, Inc. | Identification of VSIG8 as the putative VISTA receptor (V-R) and use thereof to produce VISTA/VSIG8 agonists and antagonists |
US10745467B2 (en) | 2010-03-26 | 2020-08-18 | The Trustees Of Dartmouth College | VISTA-Ig for treatment of autoimmune, allergic and inflammatory disorders |
US10899836B2 (en) | 2016-02-12 | 2021-01-26 | Janssen Pharmaceutica Nv | Method of identifying anti-VISTA antibodies |
US10933115B2 (en) | 2012-06-22 | 2021-03-02 | The Trustees Of Dartmouth College | VISTA antagonist and methods of use |
US11009509B2 (en) | 2015-06-24 | 2021-05-18 | Janssen Pharmaceutica Nv | Anti-VISTA antibodies and fragments |
US11014987B2 (en) | 2013-12-24 | 2021-05-25 | Janssen Pharmaceutics Nv | Anti-vista antibodies and fragments, uses thereof, and methods of identifying same |
US11123426B2 (en) | 2014-06-11 | 2021-09-21 | The Trustees Of Dartmouth College | Use of vista agonists and antagonists to suppress or enhance humoral immunity |
US11155618B2 (en) | 2018-04-02 | 2021-10-26 | Bristol-Myers Squibb Company | Anti-TREM-1 antibodies and uses thereof |
US11160260B2 (en) | 2018-04-17 | 2021-11-02 | The Curators Of The University Of Missouri | Methods for protecting porcine fetuses from infection with porcine reproductive and respiratory syndrome virus (PRRSV) |
US11180557B2 (en) | 2012-06-22 | 2021-11-23 | King's College London | Vista modulators for diagnosis and treatment of cancer |
US11230697B2 (en) | 2006-09-01 | 2022-01-25 | Therapeutic Human Polyclonals Inc. | Enhanced expression of human or humanized immunoglobulin in non-human transgenic animals |
US11242392B2 (en) | 2013-12-24 | 2022-02-08 | Janssen Pharmaceutica Nv | Anti-vista antibodies and fragments |
WO2022109316A1 (en) | 2020-11-20 | 2022-05-27 | Revivicor, Inc. | Multi-transgenic pigs with growth hormone receptor knockout for xenotransplantation |
US11525000B2 (en) | 2016-04-15 | 2022-12-13 | Immunext, Inc. | Anti-human VISTA antibodies and use thereof |
WO2023044100A1 (en) | 2021-09-20 | 2023-03-23 | Revivicor, Inc. | Multitran scenic pigs comprising ten genetic modifications for xenotransplantation |
Families Citing this family (46)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7304204B2 (en) | 1995-08-31 | 2007-12-04 | Roslin Institute | Ungulates produced by nuclear transfer of G1 cells |
GB9517780D0 (en) * | 1995-08-31 | 1995-11-01 | Roslin Inst Edinburgh | Biological manipulation |
GB9517779D0 (en) * | 1995-08-31 | 1995-11-01 | Roslin Inst Edinburgh | Biological manipulation |
US20090092588A1 (en) * | 1997-01-10 | 2009-04-09 | University Of Massachusetts As Represented By Its Amherst Campus | Cloned ungulate embryos and animals, use of cells, tissues and organs thereof for transplantation therapies including parkinson's disease |
EP1818397A1 (en) * | 1998-11-02 | 2007-08-15 | Trustees Of Tufts College | Methods for cloning animals |
US7531715B1 (en) * | 1999-01-13 | 2009-05-12 | Ppl Therapeutics (Scotland) | Double nuclear transfer method and results thereof |
US20020012660A1 (en) * | 1999-03-04 | 2002-01-31 | Alan Colman | Method of preparing a somatic cells for nuclear transfer |
KR100368435B1 (en) * | 1999-06-30 | 2003-01-24 | 황우석 | Method of cell fusion for producing a clone animal using somatic cell |
KR100414043B1 (en) * | 1999-06-30 | 2004-01-13 | 황우석 | Clone animal reproduced from somatic cell and method for production thereof |
AU1777301A (en) * | 1999-11-19 | 2001-05-30 | Hematech, Llc | Production of ungulates, preferably bovines that produce human immunoglobulins |
US7074983B2 (en) | 1999-11-19 | 2006-07-11 | Kirin Beer Kabushiki Kaisha | Transgenic bovine comprising human immunoglobulin loci and producing human immunoglobulin |
US7820878B2 (en) * | 1999-11-19 | 2010-10-26 | Kyowa Hakko Kirin Co., Ltd. | Production of ungulates, preferably bovines that produce human immunoglobulins |
US7414170B2 (en) * | 1999-11-19 | 2008-08-19 | Kirin Beer Kabushiki Kaisha | Transgenic bovines capable of human antibody production |
AU2001261650A1 (en) * | 2000-05-15 | 2001-11-26 | Geron Corporation | Ovine tissue for xenotransplantation |
US7491534B2 (en) * | 2000-12-22 | 2009-02-17 | Kirin Holdings Kabushiki Kaisha | Methods for altering cell fate to generate T-cells specific for an antigen of interest |
US20020142397A1 (en) * | 2000-12-22 | 2002-10-03 | Philippe Collas | Methods for altering cell fate |
MXPA03005624A (en) * | 2000-12-22 | 2004-12-03 | Vaurox Llc | Methods for cloning mammals using reprogrammed donor chromatin or donor cells. |
MXPA03006751A (en) | 2001-01-30 | 2005-04-08 | Amy K Rebholtz | Systems of transferring embryos and managing recipients. |
US7126039B2 (en) * | 2001-03-21 | 2006-10-24 | Geron Corporation | Animal tissue with carbohydrate antigens compatible for human transplantation |
US7265262B2 (en) * | 2001-03-21 | 2007-09-04 | Roslin Institute (Edinburgh) | Telomerizing nuclear donor cells and improving the efficiency on nuclear transfer |
EP1406917A4 (en) * | 2001-06-15 | 2007-11-14 | New Century Pharmaceuticals | Human albumin animal models for drug evaluation, toxicology and immunogenicity studies |
US20030211603A1 (en) * | 2001-08-14 | 2003-11-13 | Earp David J. | Reprogramming cells for enhanced differentiation capacity using pluripotent stem cells |
US20030224380A1 (en) * | 2001-10-25 | 2003-12-04 | The General Hospital Corporation | Genes and polymorphisms on chromosome 10 associated with Alzheimer's disease and other neurodegenerative diseases |
AU2002364945A1 (en) * | 2001-10-25 | 2003-07-09 | Neurogenetics, Inc. | Genes and polymorphisms on chromosome 10 associated with alzheimer's disease and other neurodegenerative diseases |
US20030170678A1 (en) * | 2001-10-25 | 2003-09-11 | Neurogenetics, Inc. | Genetic markers for Alzheimer's disease and methods using the same |
CA2473909A1 (en) * | 2002-01-15 | 2003-07-24 | Advanced Cell Technology, Inc. | Cloning b and t lymphocytes |
US20050090004A1 (en) * | 2003-01-16 | 2005-04-28 | Sayre Chauncey B. | Stem cell maturation for all tissue lines |
US20030134422A1 (en) * | 2002-01-16 | 2003-07-17 | Sayre Chauncey Bigelow | Stem cell maturation for all tissue lines |
US20050170506A1 (en) * | 2002-01-16 | 2005-08-04 | Primegen Biotech Llc | Therapeutic reprogramming, hybrid stem cells and maturation |
US20030217378A1 (en) * | 2002-04-05 | 2003-11-20 | The University Of Georgia Research Foundation, Inc | Cloning using rapidly matured oocytes |
AU2003286442A1 (en) * | 2002-10-16 | 2004-05-04 | Advanced Cell Technology, Inc. | Methods using gene trapped stem cells for marking pathways of stem cell differentiation and making and isolating differentiated cells |
US7682828B2 (en) * | 2003-11-26 | 2010-03-23 | Whitehead Institute For Biomedical Research | Methods for reprogramming somatic cells |
US20070011603A1 (en) * | 2005-07-06 | 2007-01-11 | Mikko Makela | Method, system, device and software product for showing tooltips for page segments and generating content for the page segments |
KR101398220B1 (en) * | 2006-10-30 | 2014-05-22 | 건국대학교 산학협력단 | Methods for producing transgenic embryos |
WO2008085891A1 (en) * | 2007-01-05 | 2008-07-17 | Worcester Polytechnic Institute | Oocyte spindle-associated factors improve somatic cell cloning |
CA3071055A1 (en) | 2007-04-07 | 2008-10-16 | Whitehead Institute For Biomedical Research | Reprogramming of somatic cells |
WO2008134522A1 (en) * | 2007-04-26 | 2008-11-06 | President And Fellows Of Harvard College | Deriving embryonic stem cells |
WO2008144580A2 (en) * | 2007-05-17 | 2008-11-27 | Oregon Health & Science University | Primate stem cells produced by somatic cell nuclear transfer |
US20090111764A1 (en) * | 2007-10-25 | 2009-04-30 | Searete Llc, A Limited Liability Corporation Of The State Of Delaware | Mitochondrial selection |
KR100915397B1 (en) * | 2008-02-22 | 2009-09-03 | 삼성전자주식회사 | Cover member, developing cartridge and developing unit for image forming apparatus |
EP2300611B1 (en) | 2008-06-13 | 2017-08-09 | Whitehead Institute for Biomedical Research | Programming and reprogramming of cells |
CA2759608A1 (en) | 2009-04-24 | 2010-10-28 | Oregon Health & Science University | Methods for mitochondrial dna replacement in oocytes |
US9420770B2 (en) | 2009-12-01 | 2016-08-23 | Indiana University Research & Technology Corporation | Methods of modulating thrombocytopenia and modified transgenic pigs |
WO2012051699A1 (en) | 2010-10-22 | 2012-04-26 | Agri-Neo Inc. | Synergistic activity of peracetic acid and at least one sar inducer for the control of pathogens in and onto growing plants |
KR101352641B1 (en) | 2010-11-08 | 2014-01-17 | 광주과학기술원 | Chemically-Defined Methods for Preparing Multipotent Cells Derived from Terminally Differentiated Skeletal Muscle and Uses Thereof |
US10136642B2 (en) | 2015-02-19 | 2018-11-27 | Agri-Neo, Inc. | Composition of peracetic acid and at least one organic fungicide for the control and/or the treatment of diseases associated with the presence of pathogens, and method, use and kit involving said composition |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1994006422A1 (en) * | 1992-09-22 | 1994-03-31 | The Government Of The United States Of America As Represented By The Secretary, Department Of Health And Human Services | Use of taxol for treating lymphomas and breast cancer |
WO1995003795A1 (en) * | 1993-07-29 | 1995-02-09 | The Government Of The United States Of America, Represented By The Secretary, Department Of Health And Human Services | Method of treating atherosclerosis or restenosis using microtubule stabilizing agent |
Family Cites Families (26)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1030255A (en) * | 1987-04-14 | 1989-01-11 | 路明尼斯有限公司 | The animal of metastatic gene |
US5057420A (en) | 1987-06-05 | 1991-10-15 | Granada Biosciences, Inc. | Bovine nuclear transplantation |
CA2059199A1 (en) | 1992-01-10 | 1993-07-11 | Steen Willadsen | Method for producing mature reconstituted mammalian eggs by nuclear transplantation |
GB2265909B (en) | 1992-04-01 | 1996-03-20 | Inst Of Animal Physiology And | Fusion of donor nucleus with recipient cytoplast in the absence of calcium ion |
CA2092258A1 (en) | 1992-12-30 | 1994-07-01 | Steven L. Stice | Synchronized donor cells for bovine nuclear transfer |
US5480772A (en) | 1993-02-03 | 1996-01-02 | Brandeis University | In vitro activation of a nucleus |
US5496720A (en) | 1993-02-10 | 1996-03-05 | Susko-Parrish; Joan L. | Parthenogenic oocyte activation |
US5523226A (en) | 1993-05-14 | 1996-06-04 | Biotechnology Research And Development Corp. | Transgenic swine compositions and methods |
US5333948A (en) | 1993-06-22 | 1994-08-02 | Tekonsha Engineering Company | Multiple-gain electronic brake actuator with trigger point inertial sensor |
WO1995017500A1 (en) | 1993-12-23 | 1995-06-29 | Abs Global, Inc. | Embryonic stem cells as nuclear donors and nuclear transfer techniques to produce chimeric and transgenic animals |
GB9417831D0 (en) | 1994-09-05 | 1994-10-26 | Biotech & Biolog Scien Res | Biological manipulation |
GB9517779D0 (en) | 1995-08-31 | 1995-11-01 | Roslin Inst Edinburgh | Biological manipulation |
GB9517780D0 (en) | 1995-08-31 | 1995-11-01 | Roslin Inst Edinburgh | Biological manipulation |
US7304204B2 (en) | 1995-08-31 | 2007-12-04 | Roslin Institute | Ungulates produced by nuclear transfer of G1 cells |
US6215041B1 (en) | 1997-01-10 | 2001-04-10 | University Of Mmassachusetts | Cloning using donor nuclei from a non-quiesecent somatic cells |
US6235969B1 (en) | 1997-01-10 | 2001-05-22 | University Of Massachusetts | Cloning pigs using donor nuclei from non-quiescent differentiated cells |
US5945577A (en) | 1997-01-10 | 1999-08-31 | University Of Massachusetts As Represented By Its Amherst Campus | Cloning using donor nuclei from proliferating somatic cells |
US7291764B1 (en) | 1997-01-10 | 2007-11-06 | University of Massachusetts, a Public Institution of Higher Education of the Commonwealth of Massachusetts, as Represented by its Amherst Campus, Office of Vice Chancellor for Research at Amherst | Cloning pigs using non-quiescent differentiated donor cells or nuclei |
US7361804B1 (en) * | 1997-02-19 | 2008-04-22 | Roslin Institute (Edinburgh) | Unactivated oocytes in nuclear transfer to produce ungulates |
US6011197A (en) | 1997-03-06 | 2000-01-04 | Infigen, Inc. | Method of cloning bovines using reprogrammed non-embryonic bovine cells |
WO1999036510A1 (en) | 1998-01-16 | 1999-07-22 | Agrobiogen Gmbh | Efficient nuclear transfer using fetal fibroblasts |
JP3573964B2 (en) * | 1998-06-17 | 2004-10-06 | 三洋電機株式会社 | Method of manufacturing hydrogen storage alloy electrode for alkaline battery and hydrogen storage alloy electrode for alkaline storage battery |
WO2000022098A1 (en) * | 1998-10-12 | 2000-04-20 | Geron Bio-Med Limited | Porcine oocytes with improved developmental competence |
US6700037B2 (en) | 1998-11-24 | 2004-03-02 | Infigen, Inc. | Method of cloning porcine animals |
US20050156424A1 (en) * | 2000-02-29 | 2005-07-21 | Thyssenkrupp Presta Ag | Steering column and manufacturing method thereof |
US8302202B2 (en) * | 2005-08-03 | 2012-10-30 | International Business Machines Corporation | Transportable computing environment apparatus system and method |
-
1995
- 1995-08-31 GB GBGB9517779.6A patent/GB9517779D0/en active Pending
-
1996
- 1996-08-30 CN CNA2005101270278A patent/CN1772891A/en active Pending
- 1996-08-30 ES ES96928586T patent/ES2309989T3/en not_active Expired - Lifetime
- 1996-08-30 SG SG1999000941A patent/SG75919A1/en unknown
- 1996-08-30 ZA ZA9607383A patent/ZA967383B/en unknown
- 1996-08-30 NZ NZ335407A patent/NZ335407A/en not_active IP Right Cessation
- 1996-08-30 CA CA002229657A patent/CA2229657A1/en not_active Abandoned
- 1996-08-30 KR KR1020057014691A patent/KR100743006B1/en active IP Right Grant
- 1996-08-30 KR KR1019980701382A patent/KR100533477B1/en active IP Right Grant
- 1996-08-30 CN CNB961978929A patent/CN1250715C/en not_active Expired - Lifetime
- 1996-08-30 WO PCT/GB1996/002098 patent/WO1997007668A1/en active IP Right Grant
- 1996-08-30 NZ NZ316148A patent/NZ316148A/en not_active IP Right Cessation
- 1996-08-30 BR BR9610013-3A patent/BR9610013A/en not_active Application Discontinuation
- 1996-08-30 AU AU68309/96A patent/AU728809B2/en not_active Expired
- 1996-08-30 JP JP9509995A patent/JP2000506721A/en active Pending
- 1996-08-30 KR KR1020067006296A patent/KR20060057638A/en not_active Application Discontinuation
- 1996-08-30 CZ CZ98604A patent/CZ60498A3/en unknown
- 1996-08-30 EP EP96928586A patent/EP0847237B1/en not_active Expired - Lifetime
- 1996-08-30 AT AT96928586T patent/ATE400176T1/en not_active IP Right Cessation
- 1996-08-30 IL IL12341796A patent/IL123417A0/en unknown
- 1996-08-30 CN CN2006100037660A patent/CN1813642B/en not_active Expired - Lifetime
- 1996-08-30 DE DE69637591T patent/DE69637591D1/en not_active Expired - Lifetime
- 1996-08-30 KR KR1020077007531A patent/KR20070041793A/en not_active Application Discontinuation
- 1996-08-30 HU HU9802485A patent/HUP9802485A3/en unknown
- 1996-08-30 DK DK96928586T patent/DK0847237T3/en active
- 1996-08-30 PL PL96325336A patent/PL325336A1/en unknown
-
1997
- 1997-02-19 US US08/803,165 patent/US6252133B1/en not_active Expired - Lifetime
-
1998
- 1998-02-27 NO NO980846A patent/NO980846L/en unknown
- 1998-05-13 HK HK98104135A patent/HK1004937A1/en not_active IP Right Cessation
-
2000
- 2000-08-29 US US09/650,285 patent/US6525243B1/en not_active Expired - Lifetime
-
2001
- 2001-10-11 US US09/973,701 patent/US20030037352A1/en not_active Abandoned
-
2002
- 2002-07-09 US US10/190,617 patent/US7326824B2/en not_active Expired - Fee Related
- 2002-09-05 US US10/234,854 patent/US7321075B2/en not_active Expired - Fee Related
-
2004
- 2004-08-03 US US10/909,845 patent/US7329796B2/en not_active Expired - Fee Related
- 2004-08-10 US US10/914,161 patent/US7321076B2/en not_active Expired - Fee Related
-
2005
- 2005-03-02 US US11/068,903 patent/US7432415B2/en not_active Expired - Fee Related
- 2005-11-03 US US11/265,114 patent/US7524677B2/en not_active Expired - Fee Related
- 2005-11-30 JP JP2005345998A patent/JP2006340710A/en active Pending
-
2006
- 2006-10-06 US US11/544,038 patent/US20070028312A1/en not_active Abandoned
- 2006-10-06 US US11/543,881 patent/US7326825B2/en not_active Expired - Fee Related
-
2008
- 2008-04-22 JP JP2008111492A patent/JP2008194053A/en active Pending
-
2009
- 2009-12-24 US US12/647,316 patent/US20100146654A1/en not_active Abandoned
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1994006422A1 (en) * | 1992-09-22 | 1994-03-31 | The Government Of The United States Of America As Represented By The Secretary, Department Of Health And Human Services | Use of taxol for treating lymphomas and breast cancer |
WO1995003795A1 (en) * | 1993-07-29 | 1995-02-09 | The Government Of The United States Of America, Represented By The Secretary, Department Of Health And Human Services | Method of treating atherosclerosis or restenosis using microtubule stabilizing agent |
Non-Patent Citations (7)
Title |
---|
CAMPBELL, K.H.S. ET AL.: "Live lambs by nuclear transfer from an established cell line", THERIOGENOLOGY, vol. 45, no. 1, 7 January 1996 (1996-01-07), pages 287, XP000605648 * |
CAMPBELL, K.H.S. ET AL.: "Nuclear-cytoplasmic interactions during the first cycle of nuclear transfer reconstructed bovine embryos: implications fro desoxyribonucleic acid replication and development", BIOLOGY OF REPRODUCTION, vol. 49, no. 5, 1 November 1993 (1993-11-01), pages 933 - 942, XP000604579 * |
COLLAS, P. & ROBL, J.M.: "Factors affecting the efficiency of nuclear transplantation in the rabbit embryo", BIOLOGY OF REPRODUCTION, vol. 43, no. 5, November 1990 (1990-11-01), pages 877 - 884, XP000607321 * |
CZOLOWSKA, R. ET AL.: "Behaviour of thymocyte nuclei in non-activated and activated mouse oocytes", JOURNAL OF CELL SCIENCE, vol. 69, 1984, pages 19 - 34, XP002016866 * |
GRAHAM, C.F.: "The fusion of cells with one- and two-cell mouse embryo", THE WISTAR INSTITUTE SYMPOSIUM MONOGRAPH, vol. 9, 1 January 1969 (1969-01-01), pages 19 - 33, XP000607322 * |
OTAEGUI, P.J. ET AL.: "Transfer of nuclei from 8-cell stage mouse embryos following use of nocodazole to control the cell cycle", MOLECULAR REPRODUCTION AND DEVELOPMENT, vol. 39, no. 2, 1 October 1994 (1994-10-01), pages 147 - 152, XP000604559 * |
WILLADSEN, S.M.: "Nuclear transplantation in sheep embryos", NATURE, vol. 320, no. 6, March 1986 (1986-03-01), LONDON GB, pages 63 - 65, XP000569670 * |
Cited By (245)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6753457B2 (en) | 1993-02-03 | 2004-06-22 | Tranxenogen | Nuclear reprogramming using cytoplasmic extract |
US6878546B2 (en) | 1993-02-03 | 2005-04-12 | Brandeis University | Product and method for swelling a cell nucleus without DNA replication |
US6025155A (en) * | 1996-04-10 | 2000-02-15 | Chromos Molecular Systems, Inc. | Artificial chromosomes, uses thereof and methods for preparing artificial chromosomes |
US6077697A (en) * | 1996-04-10 | 2000-06-20 | Chromos Molecular Systems, Inc. | Artificial chromosomes, uses thereof and methods for preparing artificial chromosomes |
EP2314708A1 (en) | 1996-04-10 | 2011-04-27 | Chromos Molecular Systems, Inc. | Artificial chromosomes, uses thereof and methods for preparing artificial chromosomes |
US6369294B1 (en) | 1996-10-11 | 2002-04-09 | Texas A&M University System | Methods comprising apoptosis inhibitors for the generation of transgenic pigs |
US6271436B1 (en) | 1996-10-11 | 2001-08-07 | The Texas A & M University System | Cells and methods for the generation of transgenic pigs |
US6235969B1 (en) * | 1997-01-10 | 2001-05-22 | University Of Massachusetts | Cloning pigs using donor nuclei from non-quiescent differentiated cells |
US6235970B1 (en) * | 1997-01-10 | 2001-05-22 | University Of Massachusetts, Amherst Campus | CICM cells and non-human mammalian embryos prepared by nuclear transfer of a proliferating differentiated cell or its nucleus |
EP1808484A1 (en) * | 1997-01-10 | 2007-07-18 | University of Massachusetts, a Public Institution of Higher Education of The Commonwealth of Massachusetts, | Nuclear transfer with differentiated fetal and adult donor cells |
US5945577A (en) * | 1997-01-10 | 1999-08-31 | University Of Massachusetts As Represented By Its Amherst Campus | Cloning using donor nuclei from proliferating somatic cells |
WO1998030683A2 (en) * | 1997-01-10 | 1998-07-16 | University Of Massachusetts, A Public Institution Of Higher Education Of The Commonwealth Of Massachusetts | Nuclear transfer with differentiated fetal and adult donor cells |
WO1998030683A3 (en) * | 1997-01-10 | 1998-09-17 | Univ Massachusetts | Nuclear transfer with differentiated fetal and adult donor cells |
US6603059B1 (en) | 1997-03-06 | 2003-08-05 | Infigen, Inc. | Method of cloning animals |
US6395958B1 (en) | 1997-03-06 | 2002-05-28 | Infigen, Inc. | Method of producing a polypeptide in an ungulate |
EP1676920A2 (en) | 1997-03-26 | 2006-07-05 | Imperial College Innovations Limited | Anticoagulant fusion protein anchored to cell membrane |
EP1017423A1 (en) | 1997-07-03 | 2000-07-12 | University of Massachusetts, a Public Institution of Higher Education of The Commonwealth of Massachusetts, | Cloning pigs using donor nuclei from differentiated cells |
AU742840B2 (en) * | 1997-07-03 | 2002-01-10 | University Of Massachusetts | Cloning pigs using donor nuclei from differentiated cells |
EP1017422A1 (en) | 1997-07-03 | 2000-07-12 | University of Massachusetts, a Public Institution of Higher Education of The Commonwealth of Massachusetts, | Cloning using donor nuclei from non-serum starved, differentiated cells |
US7923015B2 (en) | 1997-08-14 | 2011-04-12 | Institut Pasteur | Methods for direct visualization of active synapses |
US7923216B2 (en) | 1997-08-14 | 2011-04-12 | Institut Pasteur | In vivo modulation of neuronal transport |
EP0930362A2 (en) * | 1997-10-28 | 1999-07-21 | Snow Brand Milk Products Co., Ltd. | Method of synchronizing epithelial cells into Go phase |
EP0930362A3 (en) * | 1997-10-28 | 2002-10-23 | Snow Brand Milk Products Co., Ltd. | Method of synchronizing epithelial cells into Go phase |
WO1999035906A1 (en) * | 1998-01-16 | 1999-07-22 | Agrobiogen Gmbh | Efficient nuclear transfer using primordial germ cells |
US7351876B2 (en) | 1998-01-16 | 2008-04-01 | Agrobiogen Gmbh Biotechnologie | Efficient nuclear transfer with primordial gametes |
JP2002500864A (en) * | 1998-01-21 | 2002-01-15 | ユニバーシティ・オブ・ハワイ | Animal term growth from enucleated oocytes reconstituted adult somatic nuclei |
WO1999037143A2 (en) * | 1998-01-21 | 1999-07-29 | University Of Hawaii | Full term development of animals from enucleated oocytes reconstituted with adult somatic cell nuclei |
US6331659B1 (en) | 1998-01-21 | 2001-12-18 | University Of Hawaii | Cumulus cells as nuclear donors |
WO1999037143A3 (en) * | 1998-01-21 | 2000-02-03 | Univ Hawaii | Full term development of animals from enucleated oocytes reconstituted with adult somatic cell nuclei |
WO1999046982A1 (en) * | 1998-03-16 | 1999-09-23 | Relag Pty Ltd | Porcine nuclear transfer |
WO1999053025A1 (en) * | 1998-04-15 | 1999-10-21 | Monash University | Method of nuclear transfer |
WO1999053751A1 (en) * | 1998-04-20 | 1999-10-28 | Consorzio Incremento Zootecnico S.R.L. | Source of nuclei for nuclear transfer |
US6143564A (en) * | 1998-07-07 | 2000-11-07 | University Of Hawaii | Use of the polar body chromosomes for the production of embryos and normal offspring |
WO2000001806A1 (en) * | 1998-07-07 | 2000-01-13 | University Of Hawaii | Use of the first polar body chromosomes for the production of embryos |
GB2356930A (en) * | 1998-09-25 | 2001-06-06 | Roslin Inst | Method of screening for large offspring syndrome |
WO2000018902A1 (en) * | 1998-09-25 | 2000-04-06 | Roslin Institute (Edinburgh) | Method of screening for large offspring syndrome |
WO2000022098A1 (en) * | 1998-10-12 | 2000-04-20 | Geron Bio-Med Limited | Porcine oocytes with improved developmental competence |
GB2365445A (en) * | 1998-10-12 | 2002-02-20 | Geron Bio Med Ltd | Porcine occcytes with improved developmental competence |
US6548741B2 (en) * | 1998-10-12 | 2003-04-15 | Geron Corporation | Developmental competence for assisted reproduction and nuclear transfer in pigs |
US6781030B1 (en) * | 1998-11-02 | 2004-08-24 | Trustee Of Tufts College, Ballou Hall | Methods for cloning mammals using telophase oocytes |
US7592503B2 (en) | 1998-11-02 | 2009-09-22 | Trustees Of Tufts College | Mammalian telophase oocyte enucleation |
WO2000030436A1 (en) | 1998-11-19 | 2000-06-02 | Ppl Therapeutics (Scotland) Ltd. | Stabilisation of milk from transgenic animals |
US6700037B2 (en) | 1998-11-24 | 2004-03-02 | Infigen, Inc. | Method of cloning porcine animals |
US6258998B1 (en) | 1998-11-24 | 2001-07-10 | Infigen, Inc. | Method of cloning porcine animals |
WO2000042174A1 (en) * | 1999-01-13 | 2000-07-20 | Ppl Therapeutics (Scotland) Limited | Double nuclear transfer method and results thereof |
US8148345B2 (en) | 1999-01-28 | 2012-04-03 | Georgia Health Sciences University Research Institute, Inc. | Composition and method for in vivo and in vitro attenuation of gene expression using double stranded RNA |
US7888325B2 (en) | 1999-01-28 | 2011-02-15 | Medical College Of Georgia Research Institute, Inc. | Composition and method for in vivo and in vitro attenuation of gene expression using double stranded RNA |
EP2301947A2 (en) | 1999-02-26 | 2011-03-30 | Millennium Pharmaceuticals, Inc. | Secreted proteins and uses thereof |
WO2000051424A2 (en) * | 1999-03-04 | 2000-09-08 | Ppl Therapeutics (Scotland) Ltd. | Genetic modification of somatic cells and uses thereof |
WO2000051424A3 (en) * | 1999-03-04 | 2001-03-22 | Ppl Therapeutics Scotland Ltd | Genetic modification of somatic cells and uses thereof |
EP2199392A3 (en) * | 1999-03-04 | 2010-12-15 | Revivicor, Inc. | Genetic modification of somatic cells and uses thereof |
EP2199392A2 (en) | 1999-03-04 | 2010-06-23 | Revivicor, Inc. | Genetic modification of somatic cells and uses thereof |
JP2002537785A (en) * | 1999-03-04 | 2002-11-12 | ピーピーエル セラピューティクス (スコットランド) リミテッド | Genetic modification of somatic cells and their use |
JP2011188873A (en) * | 1999-03-04 | 2011-09-29 | Revivicor Inc | Genetic modification of somatic cell and use thereof |
US7045677B2 (en) | 1999-06-23 | 2006-05-16 | Pharming Intellectual Property Bv | Fusion proteins incorporating lysozyme |
US6590139B1 (en) | 1999-06-30 | 2003-07-08 | Woo-Suk Hwang | Method for producing cloned cows |
WO2001000794A1 (en) * | 1999-06-30 | 2001-01-04 | Hwang, Woo-Suk | Method for producing cloned tigers by employing inter-species nuclear transplantation technique |
WO2001000793A1 (en) * | 1999-06-30 | 2001-01-04 | Hwang, Woo-Suk | Method for producing human cloned embryos by employing inter-species nuclear transplantation technique |
WO2001000795A1 (en) * | 1999-06-30 | 2001-01-04 | Hwang, Woo-Suk | A method for producing cloned cows |
EP2902414A1 (en) | 1999-06-30 | 2015-08-05 | Millennium Pharmaceuticals, Inc. | Antibodies directed against glycoprotein VI and uses thereof |
EP2322558A1 (en) | 1999-06-30 | 2011-05-18 | Millennium Pharmaceuticals, Inc. | Antibodies directed against glycoprotein VI and uses thereof |
EP2360254A1 (en) | 1999-08-23 | 2011-08-24 | Dana-Farber Cancer Institute, Inc. | Assays for screening anti-pd-1 antibodies and uses thereof |
EP2275559A2 (en) | 1999-09-28 | 2011-01-19 | Shire Human Genetic Therapies, Inc. | Optimized messenger RNA |
WO2002064799A2 (en) | 1999-09-28 | 2002-08-22 | Transkaryotic Therapies, Inc. | Optimized messenger rna |
WO2001035734A1 (en) * | 1999-11-19 | 2001-05-25 | Korea Research Institute Of Bioscience And Biotechnolgoy | An improved method for production of porcine clone embryos via somatic cell nuclear transfer |
WO2001036646A1 (en) * | 1999-11-19 | 2001-05-25 | Cancer Research Ventures Limited | Inhibiting gene expression with dsrna |
US7071372B2 (en) | 2000-01-04 | 2006-07-04 | University Of Connecticut | Method for cloning animals with targetted genetic alterations by transfer of long-term cultured male or female somatic cell nuclei, comprising artificially-induced genetic alterations, to enucleated recipient cells |
US6635802B1 (en) * | 2000-01-10 | 2003-10-21 | The Texas A&M University System | Nuclear transfer using cells cultured in serum starvation media containing apoptosis inhibitors |
US8142769B2 (en) | 2000-01-20 | 2012-03-27 | Diabcell Pty Ltd | Preparation and xenotransplantation of porcine islets |
US7122177B2 (en) | 2000-01-20 | 2006-10-17 | Diabcell Pty Ltd. | Preparation and xenotransplantation of porcine islets |
WO2001059076A2 (en) * | 2000-02-09 | 2001-08-16 | The Government Of The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Premeiotic and postmeiotic origin of teratomas: isolated teratoma stem cells for therapeutic uses |
WO2001059076A3 (en) * | 2000-02-09 | 2002-02-21 | Us Health | Premeiotic and postmeiotic origin of teratomas: isolated teratoma stem cells for therapeutic uses |
US7547818B2 (en) | 2000-03-15 | 2009-06-16 | The University Of Georgia Research Foundation, Inc. | Metaphase donor cells for effective nuclear reprogramming in mammals |
US6906238B2 (en) | 2000-03-15 | 2005-06-14 | University Of Georgia Research Foundation, Inc. | Effective nuclear reprogramming in mammals using CDK2 inhibitors |
US6673987B1 (en) | 2000-03-24 | 2004-01-06 | Geron Corporation | Strategy for maintaining pregnancy |
WO2001094636A2 (en) | 2000-06-05 | 2001-12-13 | Genetics Inst | Compositions, kits, and methods for identification and modulation of type i diabetes |
WO2002000730A2 (en) | 2000-06-28 | 2002-01-03 | Genetics Institute, Llc. | Pd-l2 molecules: novel pd-1 ligands and uses therefor |
US7129084B2 (en) | 2000-08-03 | 2006-10-31 | Therapeutic Human Polyclonals, Inc. | Production of humanized antibodies in transgenic animals |
US7169963B2 (en) | 2000-08-15 | 2007-01-30 | Board Of Trustees Of The University Of Illinois | Mammals expressing IGF-1 and alpha-lactalbumin in their milk |
EP1692936A1 (en) | 2000-10-03 | 2006-08-23 | GIE-CERBM, Centre Europeen de Recherche en Biologie et en Médecine | Method for targeted conditional DNA recombination in mice using the cre-ert2 fusion protein |
WO2002028164A3 (en) * | 2000-10-06 | 2002-07-18 | Advanced Cell Tech Inc | Cloning endangered and extinct species |
WO2002028164A2 (en) * | 2000-10-06 | 2002-04-11 | Advanced Cell Technology, Inc. | Cloning endangered and extinct species |
EP2295606A1 (en) | 2000-11-28 | 2011-03-16 | Wyeth LLC | Expression analysis of KIAA nucleic acids and polypeptides useful in the diagnosis and treatment of prostate cancer |
EP2316976A1 (en) | 2000-11-28 | 2011-05-04 | Wyeth LLC | Expression analysis of FKBP nucleic acids and polypeptides useful in the diagnosis and treatment of prostate cancer |
WO2002102997A3 (en) * | 2000-11-30 | 2003-12-24 | Stemron Inc | Isolated homozygous stem cells differentiated cells derived therefrom and materials and methods for making and using same |
WO2002102997A2 (en) * | 2000-11-30 | 2002-12-27 | Stemron Inc. | Isolated homozygous stem cells differentiated cells derived therefrom and materials and methods for making and using same |
EP2138583A1 (en) | 2000-12-22 | 2009-12-30 | Institut National De La Recherche Agronomique | Position-independent and tissue specific expression of a transgene in milk of transgenic animals |
EP1860199A2 (en) | 2001-01-12 | 2007-11-28 | Exelixis, Inc. | Modulating insulin receptor signaling |
US9051566B2 (en) | 2001-01-31 | 2015-06-09 | Alnylam Pharmaceuticals, Inc. | Post-transcriptional gene silencing using expressed double stranded RNA |
US6489536B2 (en) * | 2001-03-07 | 2002-12-03 | Director General Of National Agricultural Research Organization | Method for producing cloned bovines from cells of a bovine intramuscular preadipocyte cell line |
US8981061B2 (en) | 2001-03-20 | 2015-03-17 | Novo Nordisk A/S | Receptor TREM (triggering receptor expressed on myeloid cells) and uses thereof |
EP2388590A1 (en) | 2001-04-02 | 2011-11-23 | Dana Farber Cancer Institute | PD-1, a receptor for B7-4, and uses thereof |
WO2002079499A1 (en) | 2001-04-02 | 2002-10-10 | Wyeth | Pd-1, a receptor for b7-4, and uses therefor |
EP2261241A1 (en) | 2001-04-16 | 2010-12-15 | Wyeth Holdings Corporation | Streptococcus pneumoniae open reading frames encoding polypeptide antigens and uses thereof |
EP2258842A1 (en) | 2001-04-16 | 2010-12-08 | Wyeth Holdings Corporation | Streptococcus pneumoniae open reading frames encoding polypeptide antigens and uses thereof |
EP2258718A1 (en) | 2001-04-16 | 2010-12-08 | Wyeth Holdings Corporation | Streptococcus pneumoniae open reading frames encoding polypeptide antigens and uses thereof |
EP2278013A1 (en) | 2001-04-16 | 2011-01-26 | Wyeth Holdings Corporation | Streptococcus pneumoniae open reading frames encoding polypeptide antigens and uses thereof |
EP2277897A1 (en) | 2001-04-16 | 2011-01-26 | Wyeth Holdings Corporation | Streptococcus pneumoniae open reading frames encoding polypeptide antigens and uses thereof |
WO2002103350A1 (en) * | 2001-06-14 | 2002-12-27 | Infigen, Inc. | Methods for cloning mammals using remodeling factors |
US10731155B2 (en) | 2001-07-12 | 2020-08-04 | University Of Massachusetts | In vivo production of small interfering RNAs that mediate gene silencing |
EP2345720A2 (en) | 2001-07-12 | 2011-07-20 | University of Massachusetts | In vivo production of small interfering RNAs that mediate gene silencing |
EP1900815A2 (en) | 2001-07-12 | 2008-03-19 | University of Massachusetts | In vivo production of small interfering RNAs that mediate gene silencing |
EP2360251A2 (en) | 2001-07-12 | 2011-08-24 | University of Massachusetts | In vivo production of small interfering RNAs that mediate gene silencing |
WO2003046129A3 (en) * | 2001-11-09 | 2003-12-31 | Univ Pennsylvania | Compositions for the derivation of germ cells from stem cells and methods of use thereof |
WO2003042362A2 (en) | 2001-11-09 | 2003-05-22 | Dana-Farber Cancer Institute, Inc. | PGC-1β, A NOVEL PGC-1 HOMOLOGUE AND USES THEREFOR |
WO2003046129A2 (en) * | 2001-11-09 | 2003-06-05 | Trustees Of The University Of Pennsylvania | Compositions for the derivation of germ cells from stem cells and methods of use thereof |
WO2003085105A1 (en) * | 2002-04-01 | 2003-10-16 | Gtc Biotherapeutics, Inc. | A method for selecting cell lines to be used for nuclear transfer in mammalian species |
US7612250B2 (en) | 2002-07-29 | 2009-11-03 | Trustees Of Tufts College | Nuclear transfer embryo formation method |
EP2305836A1 (en) | 2002-08-20 | 2011-04-06 | Millennium Pharmaceuticals, Inc. | Compositions, kits and methods for identification, assessment, prevention and therapy of cervical cancer |
EP2314716A1 (en) | 2002-08-20 | 2011-04-27 | Millennium Pharmaceuticals, Inc. | Compositions, kits, and methods for identification, assessment, prevention, and therapy of cervical cancer |
EP2311978A1 (en) | 2002-08-20 | 2011-04-20 | Millennium Pharmaceuticals, Inc. | Compositions, kits, and methods for identification, assessment, prevention, and therapy of cervical cancer |
EP2311980A1 (en) | 2002-08-20 | 2011-04-20 | Millennium Pharmaceuticals, Inc. | Compositions, kits, and methods for identification, assessment, prevention, and therapy of cervical cancer |
EP2311979A1 (en) | 2002-08-20 | 2011-04-20 | Millennium Pharmaceuticals, Inc. | Compositions, kits and methods for identification, assessment, prevention and therapy of cervical cancer |
US7407792B2 (en) | 2002-10-10 | 2008-08-05 | Wyeth | Compositions, organisms and methodologies employing a novel human kinase |
US7122361B2 (en) | 2002-10-10 | 2006-10-17 | Wyeth | Compositions employing a novel human kinase |
US7208306B2 (en) | 2002-10-24 | 2007-04-24 | Wyeth | Compositions employing a novel human protein phosphatase |
US7807863B2 (en) | 2002-11-08 | 2010-10-05 | Kyowa Hakko Kirin Co., Ltd. | Transgenic bovine having reduced prion protein activity and uses thereof |
US7611839B2 (en) | 2002-11-21 | 2009-11-03 | Wyeth | Methods for diagnosing RCC and other solid tumors |
US7297525B2 (en) | 2002-11-27 | 2007-11-20 | Wyeth | Composition employing a novel human kinase |
EP2474632A2 (en) | 2002-12-20 | 2012-07-11 | Celera Corporation | Genetic polymorphisms associated with myocardial infarction, methods of detection and uses thereof |
EP2151507A1 (en) | 2002-12-20 | 2010-02-10 | Celera Corporation | Genetic polymorphisms associated with myocardial infarction, methods of detection and uses thereof |
EP2474631A2 (en) | 2002-12-20 | 2012-07-11 | Celera Corporation | Genetic polymorphisms associated with myocardial infarction, methods of detection and uses thereof |
EP2474630A2 (en) | 2002-12-20 | 2012-07-11 | Celera Corporation | Genetic polymorphisms associated with myocardial infarction, methods of detection and uses thereof |
EP2500440A2 (en) | 2002-12-20 | 2012-09-19 | Celera Corporation | Genetic polymorphisms associated with myocardial infarction, methods of detection and uses thereof |
EP1998177A2 (en) | 2003-01-06 | 2008-12-03 | Wyeth | Compositions and methods for diagnosing and treating colon cancers |
EP3502252A1 (en) | 2003-06-02 | 2019-06-26 | University of Massachusetts | Methods and compositions for controlling efficacy of rna silencing |
EP2314692A2 (en) | 2003-06-02 | 2011-04-27 | University of Massachusetts | Methods and compositions for enhancing the efficacy and specificity of RNAi |
WO2005017119A2 (en) | 2003-08-14 | 2005-02-24 | Exelixis, Inc. | Ups as modifiers of the beta catenin pathway and methods of use |
EP2261667A2 (en) | 2003-10-07 | 2010-12-15 | Millennium Pharmaceuticals, Inc. | Nucleic acid molecules and proteins for the identification, assessment, prevention, and their therapy of ovarian cancer |
EP2051077A2 (en) | 2003-10-07 | 2009-04-22 | Millennium Pharmaceuticals, Inc. | Nucleic acid molecules and proteins for the identification, assessment, prevention, and therapy of ovarian cancer |
WO2005046450A2 (en) | 2003-11-12 | 2005-05-26 | Children's Hospital Medical Center | Method for diagnosis and treatment of pulmonary disorders |
EP2386656A2 (en) | 2003-11-26 | 2011-11-16 | Celera Corporation | Genetic Polymorphisms Associated with Cardiovascular Disorders and Drug Response, Methods of Detection and Uses Thereof |
EP2386659A2 (en) | 2003-11-26 | 2011-11-16 | Celera Corporation | Genetic Polymorphisms Associated with Cardiovascular Disorders and Drug Response, Methods of Detection and Uses Thereof |
EP2186913A2 (en) | 2003-11-26 | 2010-05-19 | Celera Corporation | Genetic polymorphisms associated with cardiovascular disorders and drug response, methods of detection and uses thereof |
EP2405023A2 (en) | 2003-11-26 | 2012-01-11 | Celera Corporation | Genetic Polymorphisms Associated with Cardiovascular Disorders and Drug Response, Methods of Detection and Uses Thereof |
EP2386658A2 (en) | 2003-11-26 | 2011-11-16 | Celera Corporation | Genetic Polymorphisms Associated with Cardiovascular Disorders and Drug Response, Methods of Detection and Uses Thereof |
EP2386657A2 (en) | 2003-11-26 | 2011-11-16 | Celera Corporation | Genetic Polymorphisms Associated with Cardiovascular Disorders and Drug Response, Methods of Detection and Uses Thereof |
US7928285B2 (en) | 2004-04-22 | 2011-04-19 | Kyowa Hakko Kirin Co., Ltd. | Method of producing xenogenous antibodies using a bovine |
EP2423327A2 (en) | 2004-05-07 | 2012-02-29 | Celera Corporation | Genetic polymorphisms associated with liver fibrosis methods of detection and uses thereof |
EP2412827A2 (en) | 2004-05-07 | 2012-02-01 | Celera Corporation | Genetic polymorphisms associated with liver fibrosis methods of detection and uses thereof |
WO2005111241A2 (en) | 2004-05-07 | 2005-11-24 | Applera Corporation | Genetic polymorphisms associated with liver fibrosis methods of detection and uses thereof |
EP2412826A2 (en) | 2004-05-07 | 2012-02-01 | Celera Corporation | Genetic polymorphisms associated with liver fibrosis methods of detection and uses thereof |
EP2423326A2 (en) | 2004-05-07 | 2012-02-29 | Celera Corporation | Genetic polymorphisms associated with liver fibrosis methods of detection and uses thereof |
US8889639B2 (en) | 2004-10-22 | 2014-11-18 | Dana-Farber Cancer Institute, Inc. | Compositions and methods for modulating PGC-1β to treat lipid-related diseases and disorders |
US9273111B2 (en) | 2004-11-29 | 2016-03-01 | Universite De Lorraine | Therapeutic TREM-1 peptides |
US10603357B2 (en) | 2004-11-29 | 2020-03-31 | Bristol-Myers Squibb Company | Therapeutic TREM-1 peptides |
US8802397B2 (en) | 2004-12-10 | 2014-08-12 | Pheromonicin Biotech, Ltd. | Method of producing the polypeptide for treating virus-induced cancer |
US8802837B2 (en) | 2004-12-10 | 2014-08-12 | Pheromonicin Biotech, Ltd. | Nucleic acids molecule encoding the polypeptide for treating virus-induced cancer |
US8722050B2 (en) | 2004-12-10 | 2014-05-13 | Pheromonicin Biotech, Ltd. | Method of treating virus-induced cancer |
US8367066B2 (en) | 2004-12-10 | 2013-02-05 | Pheromonicin Biotech, Ltd | Antiviral bifunctional molecules, methods of construction and methods of treating virus-induced cancer therewith |
EP2113572A1 (en) | 2005-03-11 | 2009-11-04 | Celera Corporation | Genetic polymorphisms associated with coronary heart disease, methods of detection and uses thereof |
EP3138403A1 (en) | 2005-08-09 | 2017-03-08 | Revivicor, Inc. | Transgenic ungulates expressing ctla4-ig and uses thereof |
EP3031470A2 (en) | 2005-09-09 | 2016-06-15 | The Johns Hopkins University | Manipulation of regulatory t cell and dc function by targeting neuritin gene using antibodies, agonists and antagonists |
US9701940B2 (en) | 2005-09-19 | 2017-07-11 | Histogenics Corporation | Cell-support matrix having narrowly defined uniformly vertically and non-randomly organized porosity and pore density and a method for preparation thereof |
EP2471953A1 (en) | 2005-09-23 | 2012-07-04 | Celera Corporation | Genetic polymorphisms associated with cardiovascular disorders and drug response, methods of detection and uses thereof |
EP2471952A1 (en) | 2005-09-23 | 2012-07-04 | Celera Corporation | Genetic polymorphisms associated with cardiovascular disorders and drug response, methods of detection and uses thereof |
WO2007035953A2 (en) | 2005-09-23 | 2007-03-29 | Celera Diagnostics, Llc. | Genetic polymorphisms associated with cardiovascular disorders and drug response, methods of detection and uses thereof |
WO2007050705A2 (en) | 2005-10-26 | 2007-05-03 | Celera Diagnostics, Llc. | Genetic polymorphisms associated with alzheimer's disease, methods of detection and uses thereof |
US11230697B2 (en) | 2006-09-01 | 2022-01-25 | Therapeutic Human Polyclonals Inc. | Enhanced expression of human or humanized immunoglobulin in non-human transgenic animals |
WO2008033239A2 (en) | 2006-09-11 | 2008-03-20 | Applera | Genetic polymorphisms associated with psoriasis, methods of detection and uses thereof |
WO2008051511A2 (en) | 2006-10-20 | 2008-05-02 | Applera Corporation | Genetic polymorphisms associated with venous thrombosis, methods of detection and uses thereof |
EP2431483A1 (en) | 2006-10-20 | 2012-03-21 | Celera Corporation | Genetic polymorphisms associated with venous thrombosis, methods of detection and uses thereof |
US8663980B2 (en) | 2007-10-26 | 2014-03-04 | Janssen Biotech, Inc. | Vectors, host cells, and methods of production and uses |
US8980626B2 (en) | 2007-10-26 | 2015-03-17 | Janssen Biotech, Inc. | Vectors, host cells, and methods of production and uses |
US9206248B2 (en) | 2007-10-26 | 2015-12-08 | Janssen Biotech, Inc. | Vectors, host cells, and methods of production and uses |
WO2009061799A2 (en) | 2007-11-05 | 2009-05-14 | Celera Corporation | Genetic polymorphisms associated with liver fibrosis, methods of detection and uses thereof |
EP2602332A1 (en) | 2007-11-05 | 2013-06-12 | Celera Corporation | Genetic polymorphisms associated with liver fibrosis, methods of detection and uses thereof |
EP3048175A1 (en) | 2008-02-20 | 2016-07-27 | Celera Corporation | Genetic polymorphism associated with stroke, therapy based on the detection of the polymorphism and use of kits containing reagents for detecting the polymorphism |
WO2009114185A2 (en) | 2008-03-12 | 2009-09-17 | The Rockefeller University | Methods and compositions for translational profiling and molecular phenotyping |
EP3369827A1 (en) | 2008-03-12 | 2018-09-05 | The Rockefeller University | Methods and compositions for translational profiling and molecular phenotyping |
US8288094B2 (en) | 2008-04-09 | 2012-10-16 | Institut Pasteur | APOBEC3 mediated DNA editing |
EP2733222A1 (en) | 2008-07-09 | 2014-05-21 | Celera Corporation | Genetic polymorphisms associated with cardiovascular diseases, methods of detection and uses thereof |
EP2878680A1 (en) | 2008-07-09 | 2015-06-03 | Celera Corporation | Genetic polymorphisms associated with cardiovascular diseases, methods of detection and uses thereof |
EP3093351A1 (en) | 2008-07-09 | 2016-11-16 | Celera Corporation | Genetic polymorphisms associated with cardiovascular diseases, methods of detection and uses thereof |
WO2010080985A1 (en) | 2009-01-08 | 2010-07-15 | Dana-Farber Cancer Institute, Inc. | Compositions and methods for induced brown fat differentiation |
US8722964B2 (en) | 2009-04-23 | 2014-05-13 | Transposagen Biopharmaceuticals, Inc. | Genetically engineered or transgenic rats exhibiting a cancer phenotype due to a disruption of germline tumor suppressor genes |
EP2267153A1 (en) | 2009-05-26 | 2010-12-29 | Université Claude Bernard Lyon 1 | Identification of netrin-1 receptor unc5c gene mutation in solid cancers |
US11089765B2 (en) | 2009-07-01 | 2021-08-17 | Hera Testing Laboratories, Inc. | Genetically modified rat models for severe combined immunodeficiency (SCID) |
WO2011002988A1 (en) | 2009-07-01 | 2011-01-06 | Transposagen Biopharmaceuticals, Inc. | Genetically modified rat models for severe combined immunodeficiency (scid) |
US9314005B2 (en) | 2009-07-01 | 2016-04-19 | Transposagen Biopharmaceuticals, Inc. | Genetically modified rat models for severe combined immunodeficiency (SCID) |
US11849709B2 (en) | 2009-07-01 | 2023-12-26 | Hera Testing Laboratories, Inc. | Genetically modified rat models for severe combined immunodeficiency (SCID) |
WO2011011678A2 (en) | 2009-07-24 | 2011-01-27 | Transposagen Biopharmaceuticals, Inc. | Genetically modified rat models for cytokine-cytokine signaling pathways |
US8558055B2 (en) | 2009-07-24 | 2013-10-15 | Transposagen Biopharmaceuticals, Inc. | Genetically modified rat comprising a cytokine gene disruption and exhibiting a greater susceptibility to a cytokine-mediated autoimmune and/or inflammatory disease |
WO2011014721A2 (en) | 2009-07-30 | 2011-02-03 | Transposagen Biopharmaceuticals, Inc. | Genetically modified rat models for pharmacokinetics |
WO2011017518A2 (en) | 2009-08-05 | 2011-02-10 | Transposagen Biopharmaceuticals, Inc. | Genetically modified rat models for drug metabolism |
WO2011022634A2 (en) | 2009-08-20 | 2011-02-24 | Transposagen Biopharmaceuticals, Inc. | Genetically modified rat models for pain |
WO2011091134A2 (en) | 2010-01-22 | 2011-07-28 | Dana-Farber Cancer Institute, Inc. | Compositions,kits, and methods for identification, assessment, prevention, and therapy of metabolic disorders |
WO2011095894A2 (en) | 2010-02-04 | 2011-08-11 | Jichi Medical University | Identification, assessment, and therapy of cancers with innate or acquired resistance to alk inhibitors |
US10745467B2 (en) | 2010-03-26 | 2020-08-18 | The Trustees Of Dartmouth College | VISTA-Ig for treatment of autoimmune, allergic and inflammatory disorders |
US10781254B2 (en) | 2010-03-26 | 2020-09-22 | The Trustees Of Dartmouth College | VISTA regulatory T cell mediator protein, VISTA binding agents and use thereof |
EP3153521A1 (en) | 2010-03-26 | 2017-04-12 | Trustees of Dartmouth College | Vista regulatory t cell mediator protein, vista binding agents and use thereof |
WO2011130340A1 (en) | 2010-04-15 | 2011-10-20 | St. Jude Children's Research Hospital | Methods and compositions for the diagnosis and treatment of cancer resistant to anaplastic lymphoma kinase (alk) kinase inhibitors |
WO2011133418A1 (en) | 2010-04-19 | 2011-10-27 | Celera Corporation | Genetic polymorphisms associated with statin response and cardiovascular diseases, methods of detection and uses thereof |
EP3660508A1 (en) | 2010-04-19 | 2020-06-03 | Celera Corporation | Genetic polymorphisms associated with statin response and cardiovascular diseases |
EP3056899A1 (en) | 2010-04-19 | 2016-08-17 | Celera Corporation | Genetic polymorphisms associated with statin response and cardiovascular diseases, methods of detection and uses thereof |
WO2012061502A2 (en) | 2010-11-02 | 2012-05-10 | Celera Corporation | Genetic polymorphisms associated with venous thrombosis and statin response, methods of detection and uses thereof |
EP3495500A1 (en) | 2010-11-02 | 2019-06-12 | Celera Corporation | Genetic polymorphisms associated with venous thrombosis and statin response, methods of detection and uses thereof |
WO2012112586A1 (en) | 2011-02-14 | 2012-08-23 | Revivicor, Inc. | Genetically modified pigs for xenotransplantation of vascularized xenografts and derivatives thereof |
US11179496B2 (en) | 2011-02-14 | 2021-11-23 | Revivicor, Inc. | Genetically modified pigs for xenotransplantation of vascularized xenografts and derivatives thereof |
WO2012129198A1 (en) | 2011-03-23 | 2012-09-27 | Transposagen Biopharmaceuticals, Inc. | Genetically modified rat models for obesity and diabetes |
US9820475B2 (en) | 2011-05-16 | 2017-11-21 | The Curators Of The University Of Missouri | Porcine reproductive and respiratory syndrome virus resistant animals |
US10080353B2 (en) | 2011-05-16 | 2018-09-25 | The Curators Of The University Of Missouri | Porcine reproductive and respiratory syndrome virus resistant animals |
US11019809B2 (en) | 2011-05-16 | 2021-06-01 | The Curators Of The University Of Missouri | Porcine reproductive and respiratory syndrome virus resistant animals |
US10405526B2 (en) | 2011-05-16 | 2019-09-10 | The Curators Of The University Of Missouri | Porcine reproductive and respiratory syndrome virus resistant animals |
WO2013039996A1 (en) | 2011-09-13 | 2013-03-21 | Dana-Farber Cancer Institute, Inc. | Compositions and methods for brown fat induction and activity using fndc5 |
US9663568B2 (en) | 2012-02-15 | 2017-05-30 | Novo Nordisk A/S | Antibodies that bind peptidoglycan recognition protein 1 |
US10150809B2 (en) | 2012-02-15 | 2018-12-11 | Bristol-Myers Squibb Company | Antibodies that bind peptidoglycan recognition protein 1 |
US10906965B2 (en) | 2012-02-15 | 2021-02-02 | Novo Nordisk A/S | Methods of treating autoimmune disease or chronic inflammation wtih antibodies that bind peptidoglycan recognition protein 1 |
US10189904B2 (en) | 2012-02-15 | 2019-01-29 | Novo Nordisk A/S | Antibodies that bind and block triggering receptor expressed on myeloid cells-1 (TREM-1) |
US10906975B2 (en) | 2012-02-15 | 2021-02-02 | Novo Nordisk A/S | Methods of treating autoimmune disease or chronic inflammation with antibodies that bind and block triggering receptor expressed on myeloid cells-1 (TREM-1) |
US9000127B2 (en) | 2012-02-15 | 2015-04-07 | Novo Nordisk A/S | Antibodies that bind and block triggering receptor expressed on myeloid cells-1 (TREM-1) |
US9550830B2 (en) | 2012-02-15 | 2017-01-24 | Novo Nordisk A/S | Antibodies that bind and block triggering receptor expressed on myeloid cells-1 (TREM-1) |
US10933115B2 (en) | 2012-06-22 | 2021-03-02 | The Trustees Of Dartmouth College | VISTA antagonist and methods of use |
US11752189B2 (en) | 2012-06-22 | 2023-09-12 | The Trustees Of Dartmouth College | Vista antagonist and methods of use |
US11180557B2 (en) | 2012-06-22 | 2021-11-23 | King's College London | Vista modulators for diagnosis and treatment of cancer |
EP3421486A1 (en) | 2012-06-22 | 2019-01-02 | The Trustees Of Dartmouth College | Novel vista-ig constructs and the use of vista-ig for treatment of autoimmune, allergic and inflammatory disorders |
US11529416B2 (en) | 2012-09-07 | 2022-12-20 | Kings College London | Vista modulators for diagnosis and treatment of cancer |
WO2014039983A1 (en) | 2012-09-07 | 2014-03-13 | The Trustees Of Dartmouth College | Vista modulators for diagnosis and treatment of cancer |
US11242392B2 (en) | 2013-12-24 | 2022-02-08 | Janssen Pharmaceutica Nv | Anti-vista antibodies and fragments |
US11014987B2 (en) | 2013-12-24 | 2021-05-25 | Janssen Pharmaceutics Nv | Anti-vista antibodies and fragments, uses thereof, and methods of identifying same |
US11123426B2 (en) | 2014-06-11 | 2021-09-21 | The Trustees Of Dartmouth College | Use of vista agonists and antagonists to suppress or enhance humoral immunity |
US10179814B2 (en) | 2014-07-17 | 2019-01-15 | Novo Nordisk A/S | Site directed mutagenesis of TREM-1 antibodies for decreasing viscosity |
US11072654B2 (en) | 2014-07-17 | 2021-07-27 | Novo Nordisk A/S | Site directed mutagenesis of TREM-1 antibodies for decreasing viscosity |
US10077420B2 (en) | 2014-12-02 | 2018-09-18 | Histogenics Corporation | Cell and tissue culture container |
US11555172B2 (en) | 2014-12-02 | 2023-01-17 | Ocugen, Inc. | Cell and tissue culture container |
US10370455B2 (en) | 2014-12-05 | 2019-08-06 | Immunext, Inc. | Identification of VSIG8 as the putative VISTA receptor (V-R) and use thereof to produce VISTA/VSIG8 agonists and antagonists |
US10881086B2 (en) | 2014-12-09 | 2021-01-05 | Regeneron Pharmaceuticals, Inc. | Genetically modified mouse whose genome comprises a humanized CD274 gene |
EP3808775A1 (en) | 2014-12-09 | 2021-04-21 | Regeneron Pharmaceuticals, Inc. | Non-human animals having a humanized cluster of differentiation 274 gene |
US9913461B2 (en) | 2014-12-09 | 2018-03-13 | Regeneron Pharmaceuticals, Inc. | Genetically modified mouse whose genome comprises a humanized CD274 gene |
WO2016094481A1 (en) | 2014-12-09 | 2016-06-16 | Regeneron Pharmaceuticals, Inc. | Non-human animals having a humanized cluster of differentiation 274 gene |
US11009509B2 (en) | 2015-06-24 | 2021-05-18 | Janssen Pharmaceutica Nv | Anti-VISTA antibodies and fragments |
US10827730B2 (en) | 2015-08-06 | 2020-11-10 | The Curators Of The University Of Missouri | Pathogen-resistant animals having modified CD163 genes |
US10091975B2 (en) | 2015-08-06 | 2018-10-09 | The Curators Of The University Of Missouri | Pathogen-resistant animals having modified CD163 genes |
WO2017075329A2 (en) | 2015-10-29 | 2017-05-04 | Dana-Farber Cancer Institute, Inc. | Methods for identification, assessment, prevention, and treatment of metabolic disorders using pm20d1 and n-lipidated amino acids |
US10899836B2 (en) | 2016-02-12 | 2021-01-26 | Janssen Pharmaceutica Nv | Method of identifying anti-VISTA antibodies |
US11525000B2 (en) | 2016-04-15 | 2022-12-13 | Immunext, Inc. | Anti-human VISTA antibodies and use thereof |
US11603403B2 (en) | 2016-04-15 | 2023-03-14 | Immunext, Inc. | Anti-human vista antibodies and use thereof |
US11603402B2 (en) | 2016-04-15 | 2023-03-14 | Immunext, Inc. | Anti-human vista antibodies and use thereof |
US11649283B2 (en) | 2016-04-15 | 2023-05-16 | Immunext, Inc. | Anti-human vista antibodies and use thereof |
US11155618B2 (en) | 2018-04-02 | 2021-10-26 | Bristol-Myers Squibb Company | Anti-TREM-1 antibodies and uses thereof |
US11919954B2 (en) | 2018-04-02 | 2024-03-05 | Bristol-Myers Squibb Company | Anti-TREM-1 antibodies and uses thereof |
US11952420B2 (en) | 2018-04-02 | 2024-04-09 | Bristol-Myers Squibb Company | Nucleic acids encoding anti-TREM-1 antibodies |
US11160260B2 (en) | 2018-04-17 | 2021-11-02 | The Curators Of The University Of Missouri | Methods for protecting porcine fetuses from infection with porcine reproductive and respiratory syndrome virus (PRRSV) |
WO2022109316A1 (en) | 2020-11-20 | 2022-05-27 | Revivicor, Inc. | Multi-transgenic pigs with growth hormone receptor knockout for xenotransplantation |
WO2023044100A1 (en) | 2021-09-20 | 2023-03-23 | Revivicor, Inc. | Multitran scenic pigs comprising ten genetic modifications for xenotransplantation |
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AU728809B2 (en) | Unactivated oocytes as cytoplast recipients for nuclear transfer | |
AU716956B2 (en) | Quiescent cell populations for nuclear transfer | |
US7304204B2 (en) | Ungulates produced by nuclear transfer of G1 cells | |
US7361804B1 (en) | Unactivated oocytes in nuclear transfer to produce ungulates | |
AU2005202808B2 (en) | Unactivated oocytes as cytoplast recipients for nuclear transfer | |
AU2005202805B2 (en) | Unactivated oocytes as cytoplast recipients for nuclear transfer | |
AU2003271356B9 (en) | Quiescent cell population for nuclear transfer | |
GB2340493A (en) | Unactivated oocytes as cytoplast recipients for nuclear transfer | |
NZ504101A (en) | A method of preparing a non-human mammal comprising reconstituting a non-human mammalian embryo | |
MXPA98001645A (en) | Oocytes inactivated as receptors of cytopllasto for nuclear transfer | |
AU2005246962A1 (en) | Quiescent cell population for nuclear transfer |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
WWE | Wipo information: entry into national phase |
Ref document number: 96197892.9 Country of ref document: CN |
|
WWE | Wipo information: entry into national phase |
Ref document number: 08803165 Country of ref document: US |
|
AK | Designated states |
Kind code of ref document: A1 Designated state(s): AL AM AT AU AZ BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GE HU IL IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK TJ TM TR TT UA UG US UZ VN AM AZ BY KG KZ MD RU TJ TM |
|
AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): KE LS MW SD SZ UG AT BE CH DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI |
|
DFPE | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101) | ||
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
WWE | Wipo information: entry into national phase |
Ref document number: 1996928586 Country of ref document: EP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 316148 Country of ref document: NZ |
|
ENP | Entry into the national phase |
Ref document number: 2229657 Country of ref document: CA Ref document number: 2229657 Country of ref document: CA Kind code of ref document: A |
|
WWE | Wipo information: entry into national phase |
Ref document number: 1199800152 Country of ref document: VN |
|
WWE | Wipo information: entry into national phase |
Ref document number: 1019980701382 Country of ref document: KR |
|
WWE | Wipo information: entry into national phase |
Ref document number: PV1998-604 Country of ref document: CZ Ref document number: PA/a/1998/001645 Country of ref document: MX |
|
ENP | Entry into the national phase |
Ref document number: 1997 509995 Country of ref document: JP Kind code of ref document: A |
|
WWP | Wipo information: published in national office |
Ref document number: 1996928586 Country of ref document: EP |
|
REG | Reference to national code |
Ref country code: DE Ref legal event code: 8642 |
|
WWP | Wipo information: published in national office |
Ref document number: PV1998-604 Country of ref document: CZ |
|
WWP | Wipo information: published in national office |
Ref document number: 1019980701382 Country of ref document: KR |
|
WWR | Wipo information: refused in national office |
Ref document number: 1019980701382 Country of ref document: KR |
|
WWR | Wipo information: refused in national office |
Ref document number: PV1998-604 Country of ref document: CZ |
|
WWG | Wipo information: grant in national office |
Ref document number: 1996928586 Country of ref document: EP |